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Asthma is a complex lung disease characterized by both airway remodeling, 
which obstructs the flow of air, and chronic airway inflammation. Asthma threatens an 
individual’s ability to breathe through acute airway exacerbations during asthma attacks, 
which is also known as airway hyper-responsiveness (AHR) to allergic stimuli. Asthma 
remains poorly understood and difficult to manage, with mostly palliative treatments 
available, but no effective therapies. Therefore, understanding the mechanisms of asthma 
pathogenesis is critical to the prevention and treatment of asthma.  
Recent studies suggest that epigenetic regulation may, in part, mediate the 
complex gene-by-environment interactions that can determine the predisposition and 
severity of asthma. Epigenetic modifications are changes in gene expression that occur in 
the absence of alterations in DNA sequences, and determine cell, tissue, and organ fates 
and functions. Aberrant epigenetic mechanisms, such as DNA methylation, are often used 
as biomarkers in disease states, and are the target of many epigenetic therapies. However, 
few studies have examined epigenetic changes directly in the lung tissues in the 
pathogenesis of asthma. Previously, we observed the up-regulation of the ten-eleven 
translocation methylcytosine dioxygenase 1 (Tet1) protein in mice showing increased 
house allergen induced AHR. TET proteins are known to convert methylated DNA 
(5mC) to hydroxymethylated DNA (5hmC); therefore, we hypothesized that the up-
regulation of Tet1 contributes to allergen-induced AHR. 
 This dissertation aimed to investigate the role of Tet1 in AHR, a cardinal feature 
of asthma, in two distinct models. First, we utilized a mouse model with a heterozygous 
Tet1+/- knockout, and examined their lung and airway smooth muscle cells (ASMCs) 
 iii 
functions after acute house dust mites (HDM) exposure. Second, we translated our 
findings in the mouse model to human disease by using ASMCs isolated from non-
asthmatic and asthmatic lung donors.  We aimed to investigate whether TET1 contributes 
to the aberrant ASMC phenotypes of asthmatics, and why TET1 is dysregulated in 
asthmatics.  
In Chapter 2, we demonstrated that Tet1 deficiency in vivo protects mice from 
HDM-induced AHR. Our results indicated significant differences in TET activity, global 
DNA hydroxymethylation, and gene-specific DNA methylation in isolated mouse 
tracheal ASMCs, suggesting an association between Tet1-mediated hydroxymethylation 
and the alteration of ASMC phenotypes. Furthermore, we showed that human asthmatic 
ASMCs exhibited increased TET1 gene expression, TET activity, and global 5hmC 
content. The knockdown of TET1 by small interfering RNA (siTET1) could reverse the 
aberrant ASMC phenotypes seen in asthmatics. Additionally, in Chapter 3, we 
demonstrated that TET1 activation and its mediated ASMC phenotypes could be 
modulated via oxidative stress-dependent pathways.  
This dissertation describes the epigenetic regulation in asthma pathogenesis. Since 
epigenetic changes are potentially modifiable, these studies provide tremendous 
opportunities for the development of novel interventions for the treatment of asthma. 
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1.1. Epigenetics is the genome record of exposure  
Epigenetic mechanisms are critical responses to the environment, from famine to 
air pollution, to fine tuning gene expression patterns by modifying the genetic code to 
effect gene expression regulation, without changing the DNA sequence (1). Therefore, 
epigenetic mechanisms can interpret environmental exposures and interact with the 
genome to regulate gene expression and cellular mechanisms, tissue development, and 
organ physiology. Epigenetic mechanisms are implicated in phenotypic plasticity, or the 
ability of cells to change their behavior in response to internal and external environmental 
cues which may disrupt cellular homeostasis and result in the aberrant mechanisms 
implicated in epigenetic disease (1). Simply stated, epigenetic mechanisms are one 
answer to how the environment affects diseases, through the alteration of gene expression 
patterns.  
The classic example of a gene-environment interaction mediated by an epigenetic 
mechanism is from the Dutch Hunger Famine: during World War II, mothers who were 
starving gave birth to smaller children, which was associated with the hypomethylation of 
the insulin-like growth factor 2 (IGF2) gene (2, 3). The rationale for the modification of 
the epigenome (the epigenetic genome state) was that a smaller birth weight was 
advantageous to the newborns, since being smaller required fewer nutrients during 
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famine conditions. However, complications occur when the in utero environment does 
not match the environment at birth; thus, epigenetic reprogramming occurs based on 
environmental cues, which results in alterations in gene expression patterns and an 
increased risk of epigenetic disease. After World War II, Dutch Hunger Famine infants 
had excess nutrition, and epidemiological evidence associated the cohort with increased 
schizophrenia (4) and cardiovascular disease (5) compared to the control populations.  
There is also evidence that prenatal exposure to cigarette smoke (6, 7), polycyclic 
aromatic hydrocarbons in air pollution (8), arsenic (9), and endocrine disrupting 
chemicals (9, 10)  may have effects on the epigenetic outcomes and disease susceptibility 
in offspring. Another classic study of a gene-environment interaction comes from 
monozygotic twin studies, in which the genetic determinants were identical but the 
environments varied (11, 12). Different lifestyle choices, or environments, made each 
twin more or less susceptible to chronic disease states, suggesting that certain 
environmental exposures were interacting with genetic determinants to shape their 
disease susceptibility. Therefore, epigenetic reprogramming can trigger either somatic or 
germ line changes in the epigenome, which can affect disease susceptibility during 
development, and may be transmitted through multiple generations (13).  
 There is increasing epidemiological evidence that environmental exposures can 
alter the epigenetic mechanisms in somatic cells during development that are associated 
with altered risks of disease. By understanding the unique “signatures”, of environmental 
exposure upon the epigenome, we can gain insight into the biological mechanisms that 
are aberrant in disease development, and the opportunities to therapeutically intervene. In 
order to define the epigenetic “signatures,” we must identify the exposure, which is 
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extremely difficult in cross-sectional epidemiological studies. Nevertheless, 
epidemiological studies provide valuable insight into the aberrant epigenetic mechanisms 
associated with disease risk, although these mechanisms are often considered to be causal 
associations, and the exact mechanisms have not yet been established (14). There has 
long been an association between the regional composition of ambient air pollutants and 
the risk of asthma, including ambient nitric oxide (15), ozone (16), suspended particulate 
matter (14), diesel exhaust phthalates (15, 16), and polycyclic aromatic hydrocarbons 
(PAHs) (8). In addition to air pollution, epidemiological studies have discovered an 
association between arsenic and the exposure to heavy metals and cardiovascular health 
risks (17, 18). These epidemiological studies demonstrate the role of epigenetic 
mechanisms associated with the gene-environment interactions implicated in disease 
development. Therefore, studies into the role of environmental exposures upon epigenetic 
mechanisms provide novel insights into disease pathogenesis, therapeutic strategies, and 
public health interventions.  
 
1.1.1.   Mechanisms of epigenetic regulation 
Epigenetic mechanisms alter gene expression without changing DNA sequences, 
which means that epigenetic mechanisms act “above” or “on top” of genetics to alter 
gene transcription.  This ability to modulate transcriptional programs determines the cell 
identity, regulates molecular mechanisms, and modifies physiological responses. 
Therefore, aberrant epigenetic mechanisms lead to disruptions in gene expression 
patterns, which can contribute to altered phenotypes and disease pathogenesis.  
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 There are three main epigenetic mechanisms: DNA methylation, histone 
modifications, and microRNAs. The epigenome is composed of combinatorial events 
from all three epigenetic mechanisms, and as such, the study of epigenetic mechanisms 
with regard to transcriptional regulation is complex.  
DNA is compactly organized into nucleosomes, and in order for the 
transcriptional machinery to translate DNA, the chromatin structure must be accessible. 
Therefore, modifications (acetylation, phosphorylation, and methylation) of the histone 
tails can recruit transcription factors and enzymes to open or close the chromatin 
structure to regulate gene transcription. Once the DNA sequence is accessible, DNA 
methylation can further regulate the gene expression patterns. DNA methylation occurs in 
CG dinucleotides, usually in CpG islands, to convert the 5’ of cytosine to 5-
methylcytosine (5mC). DNA methyltransferases (DNMTs) are enzymes that are essential 
to introducing a methyl group, from an S-adenosylmethionine substrate, onto a DNA 
strand to produce 5mC. DNMT3a and DNMT3b are for de novo 5mC synthesis, while 
DNMT1 is required to maintain and propagate the modification of DNA methylation 
during DNA replication (19). DNA methylation or 5mC regulates gene transcription 
through three known mechanisms: 1) 5mC is recognized by methyl-CpG-binding domain 
(MBD) proteins, which further recruit histone modifiers to form complexes to silence 
gene expression; 2) 5mC can also inhibit transcription factor binding in the promoter 
region, and inhibit gene transcription; and 3) 5mC can block the transcriptional 
machinery (RNA polymerase) to inhibit gene transcription (20). Although DNA 
methylation is generally considered to be repressive, there are exceptions. Certain CpG 
dinucleotides are more essential to gene transcription then others, such as those critical 
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for transcription factor binding or transcriptional machinery. Therefore, DNA 
methylation is generally considered to be repressive, and the absence or loss of 
methylation would permit active gene transcription.  
In summary, both histone modifications and DNA methylation regulate the direct 
transcription of genes from the DNA sequence, by modifying the histone structure and 
transcription factor binding. However, once the genes are transcribed into mRNA 
sequences, microRNAs are able to suppress or silence gene expression, targeting specific 
mRNA sequences. Epigenetic mechanisms act upon the DNA by altering the histone 
structure to allow or prevent access to the DNA sequence, modifying the DNA sequence 
through DNA methylation to adjust transcriptional regulation and targeting mature 
mRNA sequences through microRNAs. Some combination of these epigenetic 
mechanisms is essential to regulate gene expression patterns for developmental biology, 
since all cells are derived from the same DNA sequence, yet have vastly different 
functions. Consequently, once the cell fate is determined, epigenetic mechanisms also 
occur in response to environmental cues, and these perturbations in the epigenome can 
disrupt the gene expression patterns implicated in disease mechanisms. Epigenetic 
mechanisms are modifiable, or reversible, so understanding these mechanisms in disease 
pathogenesis provides novel therapeutic opportunities.  
 
1.1.2. Therapeutic potential of epigenetic therapy 
Disease susceptibility depends on the dynamic interaction between an individual’s 
inherent genetic predisposition and their acquired epigenetic transcript. Overall, 
epigenetic drift suggests that as mammalian cells age there is a gradual global decrease in 
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DNA methylation patterns, resulting in aberrant gene expression and instability, which 
leads to increased disease susceptibility (13). For example, since the pathogenesis of 
cancer occurs over a lifetime, and usually manifests in older individuals, there have been 
extensive investigations into the epigenetic mechanisms of cancer regulation. Therefore, 
the use of epigenetic drugs or “epidrugs” has been attempted in cancer research to target 
aberrant epigenetic mechanisms. The United States Food and Drug Administration 
(FDA) has approved two DNMT inhibitors, 5-azacytidine (Vidaza) and 5-aza-2-
deoxycytidine (Decitabine), to treat myelodysplastic syndromes and three HDAC 
inhibitors, suberoylanilide hydroxamic acid (SAHA) (Vorinostat) and depsipeptide 
(Romidepsin), to treat cutaneous T-cell lymphomas, and the antiepileptic drug valproic 
acid for the treatment of leukemia, breast, and ovarian cancer (21). More epidrugs are 
currently in Phase I/II clinical trials for cancer and other disorders (13, 21). Epigenetic 
mechanisms are also being investigated in cancer therapy to predict drug absorption, 
distribution, metabolism, and excretion characteristics, as well as predict acquired drug 
resistance in chemotherapy (21). Therefore, epigenetic differences can elucidate inter-
individual variations in drug response and therapy, and also provide unique opportunities 
for personalized medicine tailored towards epigenetic abnormalities.  
Small molecule epidrugs have been effective in reversing aberrant epigenetic 
mechanisms implicated in disease pathogenesis, and in improving disease outcomes. This 
success has prompted further research into the epigenetic mechanisms underlying other 
disease mechanisms, and the opportunity for epigenetic intervention to alter the outcomes 




1.2.   Asthma and epigenetics: Public health relevance 
Asthma is a chronic inflammatory disorder of the airways, coupled with airway 
remodeling, which restricts the airflow and increases hyper-reactivity to allergens, 
resulting in increased difficulty in breathing. Asthma has become increasingly common 
and a growing proportion of severely asthmatic patients have not been responding to the 
current therapeutic options. Thus, the investigation of the epigenetic mechanisms 
implicated in asthmatic disease provides unique opportunities for therapeutic 
intervention.   
 
1.2.1. Asthmatic disease and treatment review 
Asthma is public health concern, affecting approximately 25 million people in the 
United States (235-300 million people worldwide), accounting for an estimated $18 
billion in the US for both direct and indirect costs (22, 23). The current understandings of 
asthmatic disease are that it is a chronic respiratory disorder with increased airway hyper-
responsiveness (AHR) causing airway narrowing, resulting in obstructed airways and the 
clinical manifestations of wheezing and the shortness of breath (25). Pathologically, both 
chronic inflammation and airway remodeling define asthma. The inflammatory immune 
response plays critical and divergent roles that affect many cell phenotypes, resulting in 
the hallmark increased eosinophilic inflammation of asthma. Although there is increasing 
evidence for the role of neutrophilic driven inflammation (23), we will focus mainly on 
the immune mechanism of eosinophilic inflammation. 
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Asthma is also attributed to structural changes, or airway remodeling, that 
interfere with airflow. The airway remodeling consists of airway walls that are thickened 
through increased extracellular matrix protein deposition (such as collagen and elastin), 
increased angiogenesis, and increased airway smooth muscle (ASM) mass (26). There is 
constant debate whether airway inflammation or airway remodeling occurs earlier, and 
which mechanisms are fundamental to asthma disease pathogenesis (26, 27).  
In one study of patients with asthma exposed to house dust mite allergen or 
methacholine (MCh), a bronchoconstriction agent, found that in the absence of allergen 
induced eosinophilic infiltration, both the allergen and MCh challenged lung biopsies of 
the patients exhibited increased collagen deposition and epithelial goblet cell formation 
(25). This is one of many studies highlighting the important role of bronchoconstriction 
on the structural airway changes seen in airway remodeling, rather than the inflammatory 
immune response upon the asthma pathogenesis in patients. Decades of research and 
therapeutic strategies have provided only palliative treatments, but no cure for asthma, 
suggesting that both airway inflammation and airway remodeling are interdependent 
processes underlying the clinical features of asthma (26). Therefore, a prevalent 
mechanism for asthma involves a persistent pro-inflammatory immune response in the 
large airways, which recruits and activates inflammatory cells, cytokines, and mediators 
that target structural changes in the epithelial cells and airway smooth muscle (28, 29). 
The myriad of immunological and structural changes encompassing asthma pathogenesis 
complicates the success of therapeutic intervention strategies in asthma treatment. 
Therefore, clinicians in the field have begun to characterize the asthma endotypes or 
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different asthma phenotypes attributable to specific pathophysiological mechanisms, in 
order to personalize therapeutic interventions (23).  
 The endotypes of asthma depend on the trends regarding the key Th2 cytokines 
(IL4, IL5, and IL13) and eosinophils in the blood and tissues (23). The most widely 
accepted paradigm for the increased inflammation in asthma involves a skewed pro-
inflammatory Th2 phenotype and the diminution of the anti-inflammatory Th1 
phenotype. The Th2 phenotype presents itself histologically as increased eosinophils, 
mucosal mast cells, and activated T cells in the asthmatic airways (29). The inhalation of 
antigens into the airways interacts directly with the airway epithelium, the first barrier of 
defense. Under normal conditions, the cells in the epithelium provide protection by 
inhibiting the penetration of the antigen, while also clearing the antigen through mucus 
secretion and mucociliary clearance. However, under increased allergen exposure, the 
epithelial barrier can be damaged through direct (protease activity of allergen) and 
indirect mechanisms, upon which the airway epithelial cells produce distress cytokines or 
“alarmins,” such as interleukin 33 (IL33), thymic stromal lymphopoietin (TSLP), and 
interleukin 25 (IL25), to recruit and activate dendritic cells, innate lymphoid cells, and 
basophils (23). These signals and antigens are recognized and captured by antigen-
presenting dendritic cells and presented to naïve CD4+ T cells, which then differentiate 
and proliferate into specific lineages or subsets of the CD4+ T helper cells (Th1, Th2, 
Th17, or T regulatory cells) that synthesize and secrete specific cytokines to signal a 
specialized immune response. Therefore, the interaction between the epithelial cells and 
dendritic cells is crucial for initiating the Th2 immune response (23).  
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The skewed differentiation and activation of the Th2 lineage cells results in the 
release of the pro-inflammatory cytokines implicated in the pathogenesis of asthma: IL5, 
IL13, and IL4 (28). The IL5 cytokines released from the Th2 cells primarily recruit 
eosinophils into the airways, and interact with the IL5 receptors on the cell surface of 
eosinophils to increase eosinophil activation, survival, and proliferation, which increases 
the eosinophilic expression of transforming growth factor beta (TGFβ) (23, 30, 31). 
TGFβ acts upon the myofibroblasts to increase collagen deposition, and smooth muscle 
to increase proliferation (30).  
Another pleiotropic cytokine, IL13, is released from the Th2 cells, airway smooth 
muscle, and airway epithelium, and up-regulated in asthmatic patients (32). IL13 has 
been found to act upon the airway epithelium to induce mucus hyperplasia and 
subepithelial fibrosis (23, 27, 32). IL13 and IL4 also promote IgE isotype switching in B 
cells (23, 28, 29). The plasma B cells then synthesize and release antigen specific IgE that 
binds to the mast cells and activates the release of histamine and other 
bronchoconstrictors, which recruit eosinophils into the airways (28, 29, 32). The mast 
cells also release IL4, IL5, and IL13 cytokines to amplify the proinflammatory immune 
response (29). IL4 further amplifies the immune response, since it is required to prime 
and mature the Th2 cells for differentiation and cytokine production (23, 28). In 
summary, the mediators and cytokines from the inflammatory immune response act upon 
epithelial cells, myofibroblasts, and airway smooth muscle to contribute to the structural 
changes involved in airway remodeling. Consequently, the Th2 inflammatory immune 
response is a common and dynamic phenotype of asthma patients, with a wide range of 
mediators, effectors, and targets that complicate asthma treatment. 
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 The treatment of asthma has remained largely unchanged for decades. There are 
two predominant treatments: 1) inhaled bronchodilators (short or long acting beta2-
agonists) that relax smooth muscle and 2) inhaled corticosteroids, which reduce 
inflammation (22, 23, 28). The routine adherence to these treatments is effective in 90-
95% of the population; but for severe asthmatics, these treatments even at maximum 
doses are not effective (22, 23, 29). Although beta2-agonist therapy is routinely used, 
desensitization can occur over time, due to the loss of beta adrenergic receptors on the 
cell surface, and result in severe or fatal asthmatic attacks (32). Also, there is conflicting 
evidence for the clinical effectiveness of corticosteroids to reduce airway remodeling 
(30). Interestingly, the combined use of corticosteroids and beta agonists is often 
prescribed, since corticosteroids have been shown to increase beta adrenergic receptor 
expression, and therefore, increase the effectiveness of beta2-agonists in relaxing smooth 
muscle (32).  
For severe asthmatics, these two drugs are frequently insufficient; therefore, 
endotype specific therapies have been introduced to curtail the inflammatory immune 
response in more personalized asthma therapy and management (22). For example, 
Omalizumab (Genentech/Novartis), an anti-immunoglobulin E (anti-IgE) monoclonal 
antibody, has been used in patients in clinical trials, but the results vary (22). In addition, 
Lebrikizumab (Genentech), an anti-IL13 antibody, has been shown to increase FEV1 in 
asthmatic patients, indicating improved asthma control (22, 23). Dupilumab (Regeneron) 
(an anti-IL4 receptor alpha subunit antibody), Mepolizumab (GlaxoSmithKline) (anti-IL5 
antibody), and Benralizumab (AstraZeneca/MedImmune) (anti-IL5 receptor antibody) 
have been shown in ongoing clinical trials to improve the asthma symptoms of a specific 
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subset of severe asthma patients (22, 23, 31). The anti-IL5 antibody administered to 
asthmatic patients resulted in decreased airway eosinophils, and decreased TGFβ 
expression associated with decreased extracellular matrix remodeling proteins (30). 
However, anti-IL5 administration decreased the eosinophilic infiltration by only 40-50% 
in the airways of asthmatic humans, resulting in mixed therapeutic benefits, indicating 
that there are alternative pathways to recruit, activate, and maintain eosinophils in the 
airways (30, 31). The role of innate lymphoid cells, upon activation by allergen exposure 
at the airway epithelium have been found to proliferate and release IL5 and IL13 and are 
being recognized as driving the eosinophilic asthma phenotype, independent of the Th2 
response (23). These inflammatory immune response therapies have been shown to be 
moderately successful in specific endotypes of allergic asthma patients only, due to the 
complex heterogeneity that complicates the clinical classification of asthma phenotypes 
(22, 23, 28, 31).  With regard to airway remodeling treatments, bronchial thermoplasty to 
ablate ASM mas, has been identified in experimental models to alleviate the clinical 
symptoms of asthma in dogs (22). In clinical trials, human airways treated at 65°C 
showed a 50% reduction in the airway smooth muscle mass, but no improvement in the 
pulmonary function, as measured by FEV1 (22).  
There have been many therapeutic approaches to asthma control, especially 
regarding immunomodulation, but they have had limited success in the treatment of 
asthma (29). Therefore, by further understanding the molecular mechanisms of asthma 
pathogenesis, coupled with the improved characterization of the clinical phenotypes of 
asthma, there are many opportunities to improve therapeutic intervention.   
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1.2.2. Epigenetic regulation in asthma pathogenesis 
To further complicate asthma disease mechanisms, the etiology of asthma 
involves the interactions of both genetic and environmental components. Predominantly, 
the epigenetic mechanisms involved in asthma pathogenesis have been investigated in 
experimental mouse models of allergic asthma. Ovalbumin, derived from chicken eggs, 
has been ubiquitously used as an experimental allergen to induce asthma in many 
laboratory animal models (mouse, rat, and guinea pig) (33), because an ovalbumin 
challenge invokes the increased eosinophilic inflammation, increased 
bronchoconstriction, and airway remodeling fundamental in the clinical features of 
asthma (33). Despite these experimental strengths, ovalbumin has no human relevance 
since environmental ovalbumin exposure is practically nonexistent, and therefore, not 
implicated in asthmatic disease.  
Environmentally relevant allergens, such as house dust mites (HDMs), are 
becoming more common in inducing mouse models of asthma. HDMs are considered to 
be the most prevalent allergen (34), and are pervasive in household carpets and 
mattresses with the two most common house dust mite species being Dermatophagoides 
pteronyssinus (Dp) and Dermatophagoides farina (35). Clinically, increased HDM-
specific IgE in the serum of asthmatic patients (36) supports the role of HDM induced 
allergies.  Cohort studies in Taiwan reported that more than 80% of asthmatic patients 
were found to be allergic to the Dp species of HDM (measured by HDM-specific IgE) 
(35). Moreover, HDM extract in mouse models of asthma has revealed increased 
eosinophilic driven lung inflammation and AHR (35, 37-39), similar to the ovalbumin 
mouse models that portray the clinical features of asthma. The commercially available 
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HDM extracts commonly used in mouse models contain a whole mite crushed mixture 
and fecal matter comprised of over 20 proteins or allergic components (35, 39), including 
endotoxins, proteases, and chitinases. These invade through the epithelial barrier to 
promote allergic sensitization, either directly through protease activity or indirectly by 
activating epithelial cell mediators that prime the immune response described above. The 
commercially available HDM extract does not precisely characterize the allergic 
composition of inhaled house dust mites in human exposure, since the HDM composition 
varies widely depending on the source and time of exposure (39). However, the HDM 
extract exposure does provide an environmentally relevant allergen, compared to 
ovalbumin, to examine the possible epigenetic mechanisms implicated in the 
pathogenesis of asthma.  
There have been many investigations into the epigenetic mechanisms underlying 
asthma pathogenesis (40, 41), most often focused on the modulation of the inflammatory 
immune response. The roles of epigenetic mechanisms, such as DNA methylation, have 
been implicated in the differentiation and regulation of T cells and B cells (42). In 
epidemiological studies, differential DNA methylation profiles are commonly 
investigated epigenetic mechanisms with regard to the risk of asthma. For example, 
increased urinary levels of phthalates (a commonly used plasticizer) were associated with 
an increased asthma risk in children, and correlated with the decreased DNA methylation 
of TNF-alpha and increased TNF-alpha protein (43).  
The exposure to polycyclic aromatic hydrocarbons (PAHs), formed from 
incomplete combustion and inhaled from polluted ambient air, was associated with 
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FOXP2 hypermethylation and decreased regulatory T cell (Treg) function associated with 
asthmatic children (8). Another study of African American inner-city children found that 
the peripheral blood mononuclear cells (PBMCs) in the circulating blood revealed many 
differentially methylated regions (DMRs), in which 80% of the DMRs were 
hypomethylated, including the crucial Th2 related genes IL4 and IL13; these 
hypomethylated DNA regions were associated with increased gene expression (24). 
However, clinical evidence cannot prove whether the DNA methylation, histone 
modifications, or miRNA differences observed between normal and diseased patients are 
prerequisites or manifestations of the pathogenesis of the disease (42, 44). Therefore, 
animal models are used to further investigate the epigenetic mechanisms and 
interventions to improve asthma therapy. 
Allergic animal models have shown that allergen exposure can modify the 
epigenetic mechanisms linked to disease phenotypes. Chronic ovalbumin exposure in 
C57B6 mice induced the expected asthma phenotypes, including increased AHR, airway 
inflammation, and airway remodeling, but the combined treatment of ovalbumin with 
valproic acid, an FDA approved HDAC inhibitor, resulted in decreased ovalbumin 
induced AHR, as well as decreased epithelial thickness and Tgfβ1 expression in mouse 
lungs (20). These results indicate that HDAC inhibition can reverse the epigenetic 
modifications from ovalbumin exposure, and provide protection from AHR, possibly by 
dampening the effects of Tgfβ1 on epithelial cell growth. In addition, our lab has shown 
that both acute (38) and chronic (45) HDM exposures in C57B6 mice have been shown to 
induce AHR and the associated phenotypes, as well as many differentially methylated 
genes and the aberrant gene expression related to AHR phenotypes. These are some 
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examples of the current use of animal models to elucidate epigenetic mechanisms.  
Corticosteroid treatments, routinely used to suppress inflammation in asthma 
control, work by recruiting histone deacetylase 2 (HDAC2) to multiple activated 
inflammatory genes, in which HDAC2 removes the acetylation chromatin modifications 
to abrogate the expression of the inflammatory genes (29). Therefore, asthma patients 
with corticosteroid resistance have impaired HDAC2 activity (29). In vitro, treatment 
with the drug theophylline has been shown to increase HDAC2 activity, and possibly 
increase the responsiveness to corticosteroid treatment (29). Therefore, with increased 
knowledge of the aberrant epigenetic mechanisms among patients, there is an increasing 
shift towards using epidrugs in personalized medicine, based on an individual’s 
epigenome (46).  
There is preliminary data from animal models that the inhibition of DNA 
methylation with 5-azacytidine, non-selective HDAC inhibition with trichostatin A, and 
knockout of mir-155 in ovalbumin sensitized mice have all demonstrated reduced asthma 
phenotypes, indicating the potential for epigenetic modulation in novel asthmatic therapy 
(44). There is overwhelming laboratory research and epidemiological evidence that 
suggests the diverse epigenetic roles implicated in asthma pathogenesis. However, since 
there is still no successful therapy for severe asthmatics, there is a lot of promise for 
epigenetic therapies for asthma; but first, we must thoroughly investigate the mechanisms 
responsible for the disease pathogenesis. 
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1.3. A novel epigenetic mechanism: Ten-eleven translocation methylcytosine 
dioxygenase (TET)-mediated DNA hydroxymethylation 
TET-mediated DNA hydroxymethylation is a novel epigenetic mechanism that is 
involved in the DNA demethylation pathway, and therefore, a critical enzyme involved in 
shaping the epigenome and regulating gene expression. The aberrant activities of TET 
proteins and their 5hmC products are also implicated in many disease states, and have the 
potential to be used as biomarkers for disease development. 
 
1.3.1 Role of TET in gene regulation 
 DNA methylation has been the most widely studied epigenetic mechanism; 
however, the counterpart to DNA methylation, DNA demethylation mechanisms remains 
largely unknown.  There are two proposed DNA demethylation pathways: passive and 
active. Passive DNA demethylation is simply the loss of DNA methylation during the cell 
division process, either through a mistake or aberrant maintenance methylation by 
DNMTs. Regardless of the pathway, omitting the methylation mark results in the passive 
removal or loss of DNA methylation through successive cell divisions. During zygote 
formation, there is rapid demethylation during the zygote cleavage and rapid methylation 
after implantation, independent of cell division, which indicates that active DNA 
demethylation pathways are responsible (47, 48). The discovery of ten-eleven 
translocation (TET) proteins brought incredible interest to the 5hmC-mediated DNA 
demethylation pathways, and the biological role of 5hmC in development (49). TET 
enzymes are responsible for catalyzing the oxidation of 5mC to 5hmC, and the iterative 
oxidation of 5hmC to 5-formylcytosine (5fC) and 5-carboxycytosine (5caC) DNA 
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derivatives, believed to be the intermediates in the DNA demethylation pathways (Figure 
1) (20).  
Figure 1. Chemistry of DNA methylation and hydroxymethylation. 5-Methylcytosine 
(5mC) is produced from the addition of S-adenosylmethionine (SAM) onto the 5-carbon 
of cytosine by DNA methyltransferase (DNMT). Ten-eleven translocation (TET) proteins 
then catalyze the iterative oxidation of 5mC to 5-hydroxymethylcytosine (5hmC), 5-
formlycytosine (5fC), and 5-carboxycytosine (5caC), with the required cofactors: alpha-
ketoglutarate (alpha-KG), iron (Fe 2+), and oxygen. 5hmC, 5fC, or 5caC could act as an 
intermediate in both the passive and active DNA demethylation pathways.  The active 
DNA demethylation pathway involves cytidine deaminases (AID/APOBEC) and DNA 
glycosylase enzymes (TDG/SMUG1) to generate AP site intermediates for base excision 
repair pathways, which recover an unmodified cytosine. (Adapted from Dao et al., Curr 
Environ Health Rep, 2014) 
 
TET expression levels vary between the cells and organs. TET1 and TET2 are 
highly expressed in mouse embryonic stem cells, while TET3 is seen predominantly in 
oocytes and one-cell zygotes (47). TET1 and TET3 are expressed in several adult tissues, 
but most abundant in the brain, while TET2 is enriched in hematopoietic cells (50). All of 
the TET proteins have a catalytic domain that contains both a cysteine-rich region and 2-
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oxoglutarate-Fe(II) dioxygenase activity (51-53). In mammals, TET proteins (TET1, 
TET2, and TET3) catalyze the transfer of a hydroxyl group to 5mC (52-54) to form 
5hmC/5fC/5caC. TET1 can oxidize both fully and hemi-methylated DNA, and does not 
require CpG dinucleotides (47). In the N-terminal, the CXXC domain of the TET 
proteins (TET1 and TET3 only) is a DNA binding domain, with a high affinity for 
clustered unmethylated DNA (47, 53). Subsequent genome-wide mapping of mouse and 
human embryonic stem cells has determined that the CXXC domain of TET1 overlaps 
with the unmethylated DNA generally located in the CPG islands (CGIs) of promoter 
regions (47), signaling many chromatin-associated proteins. TET mediated DNA 
hydroxymethylation can regulate gene transcription through the non-enzymatic and 
enzymatic pathways involved in the DNA demethylation pathway (20).   
Non-enzymatic regulation refers to the role of 5hmC to activate gene expression, 
without any enzymatic activity, by destabilizing the DNA structure to allow the 
transcriptional machinery to access the transcriptional start site (50). The degree of 5hmC 
content can reduce the methylation binding domain (MBD) interactions, to reorganize the 
chromatin structure and reverse the repressive effects of 5mC on transcriptional 
regulation (20).  
Enzymatic regulation refers to the role of 5hmC as the “sixth base” in DNA, and 
the critical intermediate in the active DNA demethylation pathway (55). In the DNA 
demethylation pathway, 5hmC is recognized by activation-induced cytidine deaminase 
(AID/APOBEC), which mediates the deamination of 5hmC to 5-hydroxymethlyuracil 
(5hmU), generating an abasic site. This is recognized and subsequently removed by the 
DNA glycosylases (SMUG1, single-strand-selective monofunctional uracil-DNA 
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glycosylase 1) and TDG (thymine DNA glycosylase), and the base excision repair 
machinery, to restore an unmodified cytosine (Figure 1) (47, 51).  
In summary, there are three main mechanisms that 5hmC modifications are 
generally considered to transcriptionally activate: 1) 5hmC replaces the repressive 5mC 
modifications to remove the MBD proteins and allow transcription factor binding, 2) 
5hmC is involved in the DNA demethylation pathway to recover an unmodified cytosine, 
and 3) 5hmC is suggested to recruit proteins to induce active gene transcription (20). 
Thus, TET-mediated DNA hydroxymethylation plays critical roles in altering the 
epigenome and gene regulation, which can result in both biological and disease 
consequences.  
 
1.3.2 Role of TET and DNA hydroxymethylation in disease development 
Cytosine modifications, such as 5mC and 5hmC, are epigenetic mechanisms that 
enable genes to respond to external environmental cues. Environmental exposure has 
been shown to disrupt epigenetic mechanisms and interfere with the 5mC and 5hmC 
profiles in many diseases. TET proteins are also apt to environmental perturbations; 
therefore, researchers have been investigating 5hmC content as a novel epigenetic marker 
to understand the link between epigenetic signatures and disease states.  
With regard to cancer, in tissues from the human lung, brain, kidney, liver, skin, 
and small intestine, the levels of 5hmC are remarkably depleted in the malignant tissues 
compared to the benign tissues (56-58). One explanation is that tumor formation involves 
rapid cell proliferation, which could lead to the passive loss of 5hmC (58). In addition, 
hepatocellular carcinoma samples showed that lower levels of 5hmC were associated 
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with decreased overall survival in hepatocellular carcinoma (57). Therefore, there is 
evidence for the use of 5hmC levels as novel biomarkers of disease development. The 
immunohistochemical (IHC) detection of 5hmC in human glioblastomas revealed that 
5hmC decreased significantly with the progression of the tumor grade, and that the 
reduction in 5hmC became a significant prognostic indicator of decreased life expectancy 
in fetal and adult glioblastomas (56).  
In bone marrow samples from mixed lineage leukemia (MLL)-rearranged acute 
myeloid leukemia patients (TET1 is a fusion partner of the MLL gene), TET1 was 
overexpressed (59). Additionally, in myelodysplastic syndrome (MDS), TET2 and 5hmC 
expression appear to be necessary for the normal differentiation of hematopoietic stem 
cells (60, 61). TET2 mutations in bone marrow mononuclear cells were associated with 
~16% of MDS patients, and the levels of 5hmC were significantly lower in MDS patients 
with mutant TET2 (62). After risk stratifying the 5hmC patients, it was found that higher 
5hmC levels had increased MDS survival rates when compared to those with low 5hmC 
levels (62).  
Increasing evidence has implicated the role of epigenetic modifications in 
neuropsychiatric disorders, especially since TET1 and TET3 are highly expressed in 
brain tissues. Using post-mortem brain cortex tissue from psychotic (bipolar disorder, 
schizophrenia) and depressed patients to examine the TET1 mRNA and protein 
expression, it was shown that TET1 expression levels were increased in both the 
psychotic and depressed patients when compared to the controls (63). In another study, 
the global 5hmC levels were significantly increased in psychotic patients when compared 
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to the controls (64). Altogether, these studies demonstrate that TET-mediated DNA 
hydroxymethylation generates unique epigenetic signatures that are associated with 
disease phenotypes.   
Epigenetic mechanisms provide a useful relationship to record environmental 
exposures that may interfere with disease mechanisms. Most importantly, epigenetic 
mechanisms can be reversed or modified to alter disease states, which provides 
tremendous therapeutic potential for epigenetic therapies. Asthma is a chronic 
inflammatory disease, coupled with airway remodeling, that affects many people 
worldwide, and there are no successful therapies, only palliative treatments. Although 
asthma research has focused heavily on the immunological aspects of asthma 
pathogenesis, the success rate of new immunotherapy based biologics has varied in 
patients. Therefore, an investigation into the alternative mechanisms (other than 
immunological responses) in the pathogenesis of asthma can provide useful insights into 
the disease progression.  
Currently, the exploration of the epigenetic mechanisms underlying asthma 
pathogenesis is predicted to provide novel insight into the diagnosis and treatment of 
asthma. This thesis research investigates the role of DNA hydroxymethylation, a novel 
epigenetic mechanism, in the pathogenesis of asthma. In Chapter 2, we aim to determine 
whether the experimental asthma model of Tet1-deficient mice exposed to house dust 
mite was protected from allergen-induced AHR and aberrant lung DNA methylation 
when compared to allergen-exposed wild-type mice.   Furthermore, we investigate 
whether TET1-mediated hydroxymethylation plays a role in modulating the ASM cells of 
asthmatics. In Chapter 3, we explore the underlying mechanisms of TET1 activation in 
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human ASM cells, and aim to determine if the modulation of the levels of oxidative stress 
is able to alter the epigenetic states and ASM cell phenotypes (cell proliferation, 
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 Asthma, a chronic inflammatory disease of the airways that leads to airway 
narrowing, has been recognized as having both genetic and environmental 
predispositions. Recent research has focused on the role of environmental perturbations 
on the disease pathogenesis of asthma through epigenetic modifications. Previously, in a 
mouse model, we demonstrated that house dust mite (HDM) allergen exposure induced 
airway hyper-responsiveness (AHR), and inflammatory immune responses associated 
with DNA methylation changes in the mouse lung. Here, we investigated the effects of 
the ten-eleven translocation 1 (TET1) protein, which catalyzes the oxidation of 5-
methylcytosine into 5-hydroxymethylcytosince, upon HDM-induced AHR in a Tet1+/- 
mouse model. We found that the Tet1 deficient mice were protected from HDM-induced 
AHR, and had decreased airway inflammation, collagen deposition, and mucus 
formation. In both the mouse lung and tracheal derived airway smooth muscle cells 
(ASMCs), we observed attenuation of the AHR-related gene expression and gene-
specific methylation changes, with the loss of Tet1. Furthermore, we investigated the role 
of TET1 in human ASMCs from non-asthmatic and asthmatic patients. The knockdown 
of TET1 by small-interfering RNA in asthmatic ASMCs reduced the cell proliferation and 
gene expression of PCNA, SMA, CAMK2D, ADAM33, and TGFβ2. Herein, we 
demonstrated that TET1-mediated epigenetic modifications are associated with changes 
in AHR-related phenotypes in both an experimental asthma model and human ASMCs 
from asthmatic patients. Our findings could provide insight into the epigenetic role of 
TET1 in asthma pathogenesis, and provide opportunities for novel strategies for disease 




 Asthma has become a major public health concern in developed countries, with 
the rates of diagnosis increasingly common and contributing to the third leading cause of 
hospitalization among children in the United Sates (65). Asthma is characterized by the 
exaggerated narrowing of the airways upon contact with stimuli, resulting in airway 
hyper-responsiveness (AHR) (65). Furthermore, asthma is a complex chronic 
inflammatory disease of the airways, involving increased airway smooth muscle mass, 
increased collagen deposition and increased fibrosis. These structural changes are 
referred to as airway remodeling (30, 66). Across the population, the rising rates of 
asthma susceptibility cannot be explained by genetic determinants alone (30, 65, 67). For 
individuals, the association between the relative risk of asthma and genetic determinants 
is uncertain, due to the unique environmental exposures every individual encounters (67). 
Therefore, the prevalence of asthma is proposed to be associated with both genetic and 
environmental factors, and epidemiological evidence suggests increased asthmatic risks 
or symptoms with a wide range of environmental exposures. For example, exposure to 
phthalates was associated with an increased asthma risk in children (43). Among 
phthalate-contaminated children, increased phthalate urinary metabolite mono(2-ethyl-5-
hydroxyhexyl)phthalate (5OH-MEHP) was associated with decreased TNF-alpha  DNA 
methylation and increased TNF-alpha  phthalate urinary metabolite (43). In another 
study, inner city asthmatic subjects showed many differentially methylated regions, 
compared to non-asthmatic subjects, including the hypomethylation of the IL13 and IL4 
immune genes, measured in the circulating peripheral blood mononuclear cells (PBMCs) 
(24). Additionally, in asthmatic subjects, ambient polycyclic aromatic hydrocarbon 
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(PAH) exposure from combustion sources was associated with increased FOXP3 DNA 
methylation, and decreased gene expression and protein levels of FOXP3 in T-regulatory 
immune cells (8). Furthermore, maternal exposure to PAHs was shown to be associated 
with increased cord blood ACSL3 methylation and the risk of childhood asthma (68).  
  
Epigenetic mechanisms are responsible for maintaining the diverse cellular types 
and functions from the identical genetic code in each cell. In general, there are three basic 
mechanisms of epigenetic regulation, 1) DNA methylation, 2) histone modifications, and 
3) microRNAs; they all work dynamically to regulate gene transcription. DNA 
methylation, the most widely studied epigenetic modification, involves the covalent 
addition of a methyl group from S-adnenosyl methionine (SAM) to the C5 position of 
cytosine in CpG dinucleotides, which results in a bulky methyl group that blocks the 
transcription factor or transcriptional machinery binding to repress gene transcription (2, 
20). Therefore, alterations in the epigenetic mechanisms can disrupt the epigenome 
(epigenetic genome) and dysregulate gene transcription, which may lead to the aberrant 
cell phenotypes implicated in disease pathogenesis. In asthma, aberrant DNA 
demethylation and chromatin modification are widely studied and associated with 
increased Th2 gene expression and chronic inflammation (42, 69-71), this skewed Th2 
phenotype is a hallmark of asthma pathogenesis. Nevertheless, few studies have 
examined epigenetic changes in lung tissue directly. 
   
Previously, we demonstrated that an allergen challenge with HDM induced an 
allergic asthma phenotype in mice that was associated with epigenetic changes (38, 45). 
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HDM is a ubiquitous environmental allergen commonly found in carpets and mattresses 
inside the home (35). In animal models, an HDM-challenge induced an allergic asthma 
phenotype, increasing airway hyper-responsiveness (AHR), airway smooth muscle 
(ASM) hyperplasia, and allergic inflammation (33, 35, 37, 38). We demonstrated that 
global increases in DNA hydroxymethylation were coupled with decreased gene specific 
DNA methylation in both lung tissues and tracheal ASM cells isolated from HDM-
exposed mice. Furthermore, the expression levels of differentially methylated genes were 
associated with aberrant ASM cell phenotypes. Upon examining a broad range of 
epigenetic components that could be responsible for the DNA methylation changes from 
HDM exposure, we identified the increased expression of the genes involved in the DNA 
demethylation pathways: TET1 (ten-eleven translocation protein or 5-methylcytosine 
dioxygenase 1), AID (activation-induced cytidine deaminase), and SMUG1 (single-
strand-selective monofunctional uracil-DNA glycosylase 1) with HDM-exposure (45). 
These results indicated that alterations in DNA hydroxymethylation (a possible 
intermediate in the DNA demethylation pathway) may contribute to the increased AHR 
in mice.   
  
DNA hydroxymethylation is mediated by a family of TET proteins (TET1, TET2, 
and TET3), which are made up of 2-oxoglutarate-Fe(II)dioxygenase that catalyzes the 
addition of a hydroxyl group onto methylated DNA, converting 5mC (5-methylcytosine) 
into 5hmC (5-hydoxymethylcytosine) (20, 72). In addition, 5hmC is a demethylation 
intermediate that can be iteratively oxidized by TET proteins to form the additional 
intermediates 5-formylcytosine (5fC) or 5-carboxylcytosine (5caC) (20, 72). 5hmC, and 
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possibly its intermediates, can undergo deamination (AID/APOBEC enzymes) followed 
by base excision repair (TDG/SMUG1) to remove the DNA methylation moiety and 
generate cytosine (60). Furthermore, 5hmC, and possibly its intermediates, can passively 
remove DNA methylation through the inability to replicate the 5mC modification during 
DNA replication (60). Therefore, TET proteins are required to catalyze 5mC into 5hmC, 
a key epigenetic modifier in the DNA demethylation pathway. TET-mediated DNA 
hydroxymethylation may play critical roles in regulating DNA methylation changes in 
the epigenome to alter gene transcription profiles, resulting in aberrant phenotypes. TET 
proteins can remove repressive DNA methylation markers, and therefore, permit 
transcription factor and RNA polymerase binding to increase gene transcription. 
Consequently, the role of TET proteins in DNA hydroxymethylation has been implicated 
as a novel epigenetic mechanism and biomarker of disease (2, 20). This suggests that 
understanding the TET-mediated DNA hydroxymethylation in disease development may 
provide unique therapeutic opportunities for curing disease.  
  
There are few mouse models to investigate the effects of the Tet family of 
proteins in vivo. Mice with the whole body knockout of Tet2 are fertile and viable, but 
during development approximately 34% of the Tet2+/– and 8% of the Tet2–/– mice died of 
lethal myeloid malignancies (73). In addition, conditional Tet2 mutant models displayed 
increased susceptibility to chronic myelomonocytic leukemia and increased mortality 
during development (74). Clinical findings indicate that among human hematopoietic 
malignancies and diseases, there are prevalent mutations and deficiencies in the Tet2 
protein (74-76), thereby supporting the biological relevance of the Tet2 mouse model 
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findings. Tet3 proteins are essential for embryonic development; therefore, the 
homozygous mutation of Tet3 leads to neonatal lethality (77). The double knockout 
mouse model of Tet1 and Tet2 proteins showed increased perinatal lethality when 
compared to a single Tet1 or Tet2 knockout (78), further indicating that Tet1 and Tet2 
proteins are required for postnatal development. We employed mixed background 
C57BL/6J x 129S4/SvJae Tet1+/- mice that were heterozygous for the targeted Tet1 
mutation at exon 4, which contained the catalytic domain (79). Using the same Tet1+/– or 
Tet1–/– mouse model, researchers demonstrated that the ablation of Tet1 in mouse brains 
caused impaired memory extinction and significantly down-regulated the neuronally 
related genes in the hippocampus and cortex, although these mice displayed similar gross 
morphology and behavioral assessments when compared to those of Tet1+/+ (80). 
Therefore, the use of the genetic knockout model of Tet1 may allow us to investigate the 
physiological effects of Tet1 during development or disease pathogenesis.    
  
In this study, we aimed to examine the role of Tet1 upon HDM-induced AHR. We 
exposed both Tet1 wild-type (Tet1+/+) and heterozygous (Tet1+/-) mice to HDM, and 
examined the phenotypes of AHR and DNA methylation changes in both the lungs and 
isolated tracheal ASM cells. In addition, we determined whether the knockdown of TET1 
in human ASMCs could modulate the aberrant ASM cell phenotypes seen in asthmatics. 
Our findings may provide insight into the novel epigenetic mechanisms that regulate 











All of the experimental procedures used in this study were approved by the Institutional 
Animal Care and Use Committee of Johns Hopkins University (Baltimore, MD) 
(MO14H241). For the generation of the heterozygous Tet1+/- knockout, adult Tet1+/- 
female mice from the C57BL/6J/129S4/SvJae (B6/SV129) strain were bred to Tet1+/+ 
control wild-type male mice from strain B6/SV129. Both the heterozygous and wild-type 
control mice were obtained from Jackson Laboratories (Bar Harbor, ME). The litters 
were weaned at 21 days of age, and genotyped before they were used for the proposed 
experiments. All of the mice were housed under controlled lighting (12 h light and 12 h 
dark) and temperature (21–22°C) conditions. The mice were housed in polysulfone-
ventilated cages (Technoplast, Exton, PA), and provided with Harlan’s Teklad Global 
18% Protein Extruded Rodent Diet 2018SX and fresh water ad libitum.   
Tet1+/- mice and genotyping 
DNA was extracted from tail snips (<5 mm) that were collected from mouse pups that 
were less than 21 days old, using the AccuStart II Mouse Genotyping Kit (Quanta 
Biosciences, Gaithersburg, MD). The genotypes were analyzed from the DNA extract 
with endpoint PCR using the primers provided by Jackson Laboratories: TET1 mutant 
primer (5’ AAC TGA TTC CCT TCG TGC AG 3’), wild-type forward primer (5’ TCA 
GGG AGC TCA TGG AGA CTA 3’), and common reverse primer (5’ TTA AAG CAT 
GGG TGG GAG TC 3’). The PCR cycling conditions consisted of 94°C for 90 seconds, 
followed by 35 cycles of 94°C for 30 seconds, 62°C for 45 seconds, and 72°C for 45 
seconds, with a final stage of 72°C for 2 minutes before holding at 4°C. After PCR 
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cycling, the PCR products were run on a 2% ethidium bromide (0.5 μg/mL) stained 
agarose gel, alongside a DNA ladder (New England BioLabs, Ipswich, MA), and 
visualized under UV light for the genotype analysis.   
Exposures to house allergens 
The house dust mite (HDM) extract (Dermatophagoides pteronyssinus) was purchased 
from Greer (Lenoir, NC) in a lyophilized form, before being diluted with phosphate 
buffered saline (PBS), and aliquoted appropriately so that all of the treatments in a single 
experiment used the same batch of HDM extract. Male mice, at 6 to 8 weeks of age, were 
sensitized on day 0 (treatment day) with 50 μg of HDM (diluted in 200 μL PBS) or PBS 
intraperitoneally (i.p.). Two weeks later (day 14), the mice were challenged with 50 μg of 
HDM (diluted in 50 μL PBS) or PBS (intratracheally, i.t.). For the acute HDM-induced 
airway hyper-responsiveness (AHR) model, two more HDM/PBS challenges were given 
to the mice i.t. on day 18 and day 21, for a total of 3 HDM or PBS challenges, before the 
AHR endpoints were measured on day 23.   
Pulmonary Function Test (PFT) for AHR Measurement 
Two days following the final HDM or PBS challenge, the mice were anesthetized i.p. 
with pharmaceutical grade ketamine and xylazine. After approximately 15 minutes, a 20-
gauge IV catheter was placed in the trachea and secured with a suture, and the mice were 
maintained on a mechanical ventilator delivering a constant inspiratory flow of air. The 
mice were administrated with increasing doses of aerosolized methacholine chloride 
(MCh) (Sigma-Aldrich, St. Louis, MO) (0.1, 0.3, 1, 3, 10, and 30 mg/mL) as described in 
a previous study (81), while being maintained on the ventilator. The MCh challenge was 
followed by an airway resistance measurement using a flexiVent (SCIREQ, Montreal, 
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Canada). The AHR was assessed as the change in pulmonary resistance (R 
cm/H2O/mL/s) compared to the baseline after the MCh challenge.  
 
Cardiac Puncture and Collection of Blood and Serum  
Following the MCh challenge, a cardiac puncture was performed with a 1 mL syringe 
needle filled with 10 μL of ethylenediaminetetraacetic acid (EDTA) (Quality Biological, 
Gaithersburg, MD). The blood sample was incubated with the EDTA at room 
temperature for 20 minutes before being layered on top of the Ficol-Paque (GE 
Healthcare, Uppsala, Sweden) reagent. The sample was then centrifuged at room 
temperature for 30 minutes at 5000 rpm to collect both the serum and lymphocytes. 
  
Enzyme-linked Immunosorbent Assay (ELISA) to measure the HDM-IgE in the 
Serum 
For the HDM-specific ELISA’s, HDM was diluted to 100 μg/ml and plated in 96 well-
plates overnight at 4°C. After washing, the plate was incubated with 1xPBS (with 10% 
fetal bovine serum, FBS) for 2 hours at room temperature, before the diluted (in 1xPBS 
with 10% FBS) serum samples were added and incubated overnight at 4°C. After 
washing, the diluted detection antibody (2 μg/ml) for the IgE (BioLegend, San Diego, 
CA) was added to the plate, and the plate was incubated at room temperature for 45 
minutes. Avidin peroxidase (Sigma-Aldrich, St. Louis, MO) was added to the plate, 
which was incubated for 30 minutes at room temperature before color development with 
2,2'-azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt (ABTS) 






Collection of Bronchial alveolar lavage fluid (BALF) and Cell Counts 
Following cardiac puncture, 1 mL of ice cold 1x Phosphate-buffered Saline (PBS) 
(supplemented with Pierce Protease Inhibitor Mini Tablets, EDTA-free; 
ThermoScientific, Rockford, IL) was slowly injected into the trachea using a 1 mL 
syringe without a needle, through the same secured trachea catheter for the airway 
resistance measurement. The bronchoalveolar lavage (BAL) cells collected in the 
recovered PBS from the airways were centrifuged, and further washed with the 1xPBS 
mixture. The BAL cells were resuspended in 1xPBS with protease inhibitor, and then 
stained with Turk’s solution (Ricca Chemical, Pocomoke City, MD), before being 
counted using a hemocytometer (Paul Marienfeld, Lauda-Koenigshofen, Germany). 
Subsequently, 0.1 mL of the BAL cells was added to cytology funnels (Shandon™ 
disposable cytofunnels, ThermoScientific, Rockford, IL) clamped to Superfrost Plus 
Microscope Slides (Fisher Scientific, Pittsburg, PA), and loaded into the Cytospin 
centrifuge (Shandon™ Cytospin II Cytocentrifuge, ThermoScientific, Rockford, IL) at 
600 rpm for 5 minutes and dried overnight. After drying, Cytoseal™ 60 
(ThermoScientific, Rockford, IL) adhesive was used to secure a glass cover slip onto the 
slides. Differential cell counts were obtained under light microscopy after staining with 
Hema-3 stain (Fisher Scientific, Pittsburg, PA), with a total of 400 cells (neutrophils, 
eosinophils, lymphocytes, and monocytes) counted per stained slide. 
 
Assessment of Airway Inflammation 
After the AHR measurement, the chest wall and diaphragm were exposed, and the right 
mainstem bronchus was tied off with suture. The right lung was removed, snap frozen in 
liquid nitrogen, and stored at –80°C for DNA, RNA, and protein analyses. The left lobe 
was inflated with zinc-buffered formalin (Z-Fix, 174; Anatech, Battle Creek, MI) at a 
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constant pressure of 30 cmH2O. The trachea was tied, and the lungs were excised and 
submerged in Z-fix for at least 24 hours. Then, the lungs were processed, embedded in 
paraffin using a routine histological procedure, and cut into 5 µm sections. The sections 
were subsequently stained with either hematoxylin and eosin (H&E) to assess the general 
lung morphology and inflammatory cells, Masson’s trichrome staining (MTS; American 
Mastertech Scientific, Inc.) to assess the subepithelial fibrosis and collagen deposition, or 
periodic acid-Schiff (PAS; Sigma-Aldrich) to assess the presence of the goblet cells in 
the epithelium. 
 
Tissue Collection  
After the AHR assessment in the mice, the tissues (lung, spleen, brain, and trachea) were 
harvested and processed for the gene expression analysis and immunohistochemical 
study. The right lung was excised for RNA, DNA, and nuclear protein isolation. The 
trachea was collected to isolate airway smooth muscle cells (ASMCs) as previously 
described (82).  
 
Isolation of Tracheal ASM Cells from Mice 
Immediately following collection, the tracheal tissue was placed in RPMI 1640 media 
(Corning Cellgro, Manassas, VA) supplemented with 1% penicillin-streptomycin 
(Corning Cellgro, Manassas, VA). The tracheal tissue was rinsed in RPMI 1640 media, 
and the surrounding tissue was dissected away before the tracheal segment was split 
longitudinally and placed intima side down in a 100 mm dish (with a grid to fix the 
position). Then, 5 ml of the RPMI 1640 media containing 20% FBS, 1% penicillin-
streptomycin, and 1% sodium pyruvate was added to the 100 mm dish. After 3 days of 
incubation at 37°C, the media was changed to RPMI 1640 containing 10% FBS, 1% 
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penicillin-streptomycin, and 1% sodium pyruvate. The tracheal tissue was removed when 
the outgrowing cells became locally confluent. After approximately 7-10 days, the mouse 
ASMCs were harvested and the cell purity assessed by immunocytochemistry using 
antibodies against cytokeratin, vimentin, tropomyosin, and smooth muscle actin (Santa 
Cruz Biotechnology, CA). 
 
DNA Isolation  
The DNA isolation was performed using the PureLink® Genomic DNA Mini Kit 
(Invitrogen, Carlsbad, CA), following the instructions from the manufacturer. In brief, 
50-100 mg of tissue were incubated overnight with digestion solution at 56°C to 
completely lyse the tissue before proceeding with the DNA binding, washing, and 
elution. For mammalian cells grown in the monolayer, the cells were collected from the 
culture dish and centrifuged at 2000 rpm for 3 minutes. The cells were resuspended in 
200 μL of 1xPBS, and the DNA was isolated using the PureLink® Genomic DNA Mini 
Kit (Invitrogen, Carlsbad, CA). The concentration of the isolated DNA was determined 
by using a Take3 Micro-Volume Plate (BioTeK, Winooski, VT) and quantified using the 
Gen5 analysis software in the BioTek Epoch Spectrometer system (BioTek, Winooski, 
VT). For the tissues, the integrity of the isolated DNA was assessed by running the DNA 
on an ethidium bromide (0.5 μg/mL) stained agarose gel. The DNA was visualized under 
UV light.   
 
Global 5mC and 5hmC Levels in DNA 
Two hundred ng of genomic DNA from the mouse lung tissues or cell cultures was used 
to measure the levels of 5-methyl-cytosine (5mC) and 5-hydroxymethyl-cytosine (5hmC) 
in the DNA using the 5mC DNA ELISA Kit and Quest 5hmC™ DNA ELISA Kit (Zymo 
 38 
Research, Irvine, CA). The percent of 5mC and 5hmC of the samples was quantified, 
compared to the standard curve provided in the kit.  
 
TET Activity  
The nuclear protein extracts were isolated from the cells using the EpiQuick Nuclear 
Extraction Kit (Epigentek, Farmingdale, NY). To collect the cytosolic protein, the cells 
were lysed in RIPA buffer (Cell Signaling, Danvers, MA) in the presence of a protease 
inhibitor cocktail (Invitrogen, Carlsbad, CA). The proteins were quantified for the total 
protein levels (Pierce BCA Protein Assay Kit; ThermoScientific, Rockford, IL), and 2 to 
6 μg of the total nuclear or cytosolic protein were used to measure the TET activity 
(Epigentek, Farmingdale, NY). The TET activity was assayed using the Epigenase 5mC 
Hydroxylase TET Activity/Inhibition Kit (Epigentek, Farmingdale, NY), in which the 
TET substrate was added to all of the wells and incubated at 37°C for 90 minutes. Then, 
2-6 μg of the total nuclear or cytosolic protein at a standard curve were incubated with 
the TET substrate at 37°C for 90 minutes to convert the TET substrate into the 5hmC 
product. The capture antibody was added to recognize the TET-converted products, and 
the detection antibody was incubated. Finally, for the signal detection, the colorimetric 
conversion of the developer solution was measured at 405/655 nm, and the TET activity 
was calculated compared to the standards.  
 
RNA Isolation  
For the tissues, 50-100 mg of tissue was added to pre-filled microtubes with 1.5 mm 
zirconium beads (Benchmark Scientific, Edison, NJ) with 1 mL of TRIzol (Invitrogen, 
Carlsbad, CA). The microtubes were inserted into the BeadBug Microtube Homogenizer 
(Benchmark Scientific, Edison, NJ) and vortexed at 4000 rpm for 30 seconds. 
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Afterwards, RNA was isolated following the manufacturer’s protocol for TRIzol. For the 
mammalian cells grown in the monolayer, cells were collected from the culture dish and 
centrifuged at 2000 rpm for 2 minutes. TRIzol was added directly to the cell pellet, and 
the RNA was isolated from the mammalian cell culture by the manufacturer’s protocol 
for TRIzol. The concentration of the total RNA was determined using a Take3 Micro-
Volume Plate (BioTeK, Winooski, VT) and quantified with the Gen5 analysis software in 
the BioTek Epoch Spectrometer system (BioTeK, Winooski, VT). For the tissues, the 
integrity of the isolated RNA was assessed by running the RNA on an ethidium bromide 
(0.5 μg/mL) stained agarose gel. The RNA was visualized under UV light.  
 
Real-time Reverse Transcriptase PCR (RTPCR)  
The total RNA (1 μg) was isolated from the lung tissues, isolated mouse ASMCs, and 
human ASMCs, and reverse transcribed with iScript Reverse Transcriptase (BIO-RAD, 
Hercules, CA). The mRNA levels of the genes were quantified by TaqMan-based or 
SYBR Green-based real-time PCR. The 2-ΔΔCt method was used to calculate the relative 
expression level of the transcripts normalized to RPL19. The primers are listed in Table 1 
and described in previous studies (14, 15). 
 
Methylation Specific PCR (MSPCR)  
As a starting material, 200 ng of genomic DNA was used for bisulfite treatment using the 
EZ DNA Methylation™ Kit (Zymo Research, Irvine, CA). The bisulfite treated DNA (20 
ng) was amplified with methylation specific primers using conventional PCR (GoTaq 
Green Master Mix; Promega, Madison, WI). The PCR products were loaded onto a 2% 
agarose gel for electrophoresis, and the levels of the PCR product were densitometrically 
analyzed (GelQuantNET) and standardized to β-actin. The control DNAs (fully 
 40 
methylated and fully unmethylated; Zymo Research, Irvine, CA) were mixed in various 
concentrations and served as quantification standards (0, 25, 50, 75, and 100% 
methylated DNA) when determining the methylation ratio of the samples from the PCR. 
The primers were listed in Table 1 and described in previous studies (14, 15).  
 
Cell Culture  
Human ASM cells from non-asthmatics or asthmatics were either purchased from a 
commercial vendor (Lonza, Gaithersburg, MD) or obtained from deceased donors (the 
donor demographics are listed in Table 6) from the National Disease Research 
Interchange (Philadelphia, PA), as previously described (83). The cells were received at 
Passage 3 and maintained in DMEM F-12 medium (Corning Cellgro, Manassas, VA) 
supplemented with 10% FBS (Invitrogen, Carlsbad, CA), 1% penicillin-streptomycin 
solution (Corning Cellgro, Manassas, VA), and 1% L-glutamine (Corning Cellgro, 
Manassas, VA). The cells were not used once they reached Passage 12.  
 
siRNA Transfection  
The human ASMs were grown to 70% confluence at the time of transfection. The cells 
were incubated with 50 nM siTET1, siTET2, or non-targeting control (siCTL) 
oligonucleotides using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) as the carrier for 3 
days. The sequences were as follows: siTET1 RNA oligonucleotides (Dharmacon #J-
014635-23-0010) target sequence GAGAAUAGGUAUGGUCAAA, siTET2 RNA oligos 
(Dharmacon #J-013776-25-005) target sequence CAGCAAAGGUACUUGAUAC, and 
siCTL RNA oligos which is a pool of negative control non-targeted RNA oligos 
(Dharmacon #D-001810-10-05) target sequences UGGUUUACAUGUCGACUAA, 
UGGUUUACAUGUUGUGUGA, UGGUUUACAUGUUUUCUGA, and 
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UGGUUUACAUGUUUUCCUA. After 3 days of incubation, the cells were harvested 
for the RNA (for qPCR), DNA (for 5mC and 5hmC measurements), nuclear extract (for 
TET activity), and 5-bromo-2-deoxyuridine (BrdU assay). 
 
5-Bromo-2-Deoxyuridine (BrdU) Assay for Cell Proliferation  
The human ASMCs were incubated with a 5-bromo-2'-deoxyuridine (BrdU) solution for 
six hours, according to the BrdU Cell Proliferation Assay Kit (Cell Signaling, Beverly, 
MA). The BrdU analog incorporation into the DNA was evaluated using the color 
formation measured at an absorbance of 450 nm.  
 
Statistical Analysis  
The results were expressed as the mean ± standard error mean (SEM), and Student’s t-
test was used to analyze the differences in the ASM characteristics between the non-
asthmatic and asthmatic ASM cells. For the group comparisons, a two-way ANOVA of 
multiple comparisons with Bonferroni’s or Tukey’s corrected tests were applied to 
determine if data between the treatment groups was statistically significant. The details of 
the statistical analysis are described in each data figure and table. All of the data were 
analyzed and plotted with Prism6 (GraphPad, La Jolla, CA).  
Study Approval 
All of the experimental procedures used in this study were approved by the Institutional 
Animal Care and Use Committee of the Johns Hopkins University (Baltimore, MD) 
(MO14H241). The human ASMCs from the non-asthmatics and asthmatics were either 
purchased from a commercial vendor (Lonza, Gaithersburg, MD) or obtained from 
deceased donors in accordance with the Institutional Review Board at the University of 













Increased Tet1 and 5hmC in HDM-exposed Mouse Lung and ASMCs  
  
From our previous findings, the exposure to HDM in male C57BL/6J mice 
induced airway hyper-responsiveness (AHR) and epigenetic changes in the lung genome 
(14, 15). We demonstrated the increase in the 5hmC level in the HDM-exposed mice. To 
further elucidate the existence of 5hmC in the lung following repeated HDM exposure, 
we investigated the contents of the Tet-mediated oxidation products of DNA methylation 
(5hmC, 5fC, and 5caC). Via histological assessment of the lung sections, we detected no 
significant difference in the 5mC, 5fC, and 5caC levels in either the airway epithelial or 
the ASM cells between the saline and HDM-exposed groups (Figure 1). Strikingly, the 
HDM-exposed mice showed a substantial increase in the 5hmC staining in the ASM layer 
and the inflammatory infiltrate, but not in the airway epithelium (Figure 1). Next, we 
validated the increase in the 5hmC level in multiple tissue/cell types of the lungs using 
ELISA. The HDM-exposed mice showed a significantly increased 5hmC content in the 
blood (~30% increase) and the isolated tracheal mouse ASM cells (MASMCs) (~150% 
increase) (Figure 2A) when compared to the saline control group. We found no 
significant changes in the 5mC content in the blood, BALf, and MASMCs. These results 
suggested that while inflammatory cells likely contribute to the increased 5hmC content, 
they are not the major factor, suggesting that the major 5hmC changes might occur in 
ASM cells. These results are not surprising since 5mC and 5hmC exhibit cell-type 
specific expression profiles (47).    
In addition to the global increases in 5hmC, the gene-specific changes in 5hmC 
were assayed in both the lung and ASM cells. In our previous study on methylation 
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profiling (MeDIP-seq), we identified that transforming growth factor beta 2 (Tgfβ2) 
signaling pathway was epigenetically altered by HDM exposure (45). Therefore, we 
examined whether the Tgfβ2 signaling genes, e.g. Tgfβ2, Smad2, and Smad3, showed an 
increase in DNA hydroxymethylation. The HDM-exposed mice showed 3-fold and 2-fold 
increases in the 5hmC enrichment at the lung Tgfβ2 and Smad2 promoters, respectively 
(Figure 2B). While we found no statistically significant change in the 5hmC enrichment 
at the Smad3 promoter in the lung tissues of the HDM exposed mice, there was a slight 
increase in the 5hmC enrichment at the Smad3 promoter (p=0.062) in the ASM cells.   
Hydroxymethylation of Tgfβ2 was increased by 50-fold in the ASMCs of HDM-exposed 
mice when compared to that of the saline control. Furthermore, we found that the HDM-
exposed mice showed increased enzymatic activity in the Tet proteins, in both lungs 
(~200% increase), and the MASMCs (~120% increase), when compared to the saline 
control (Figure 2C). The increase in the lung and ASMC Tet activity is in accordance 
with the increases in the 5hmC content shown in the lung sections (Figure 1) and 
MASMCs (Figure 2A). We previously reported that there was a substantial increase in 
the Tet1 expression (but not in Tet2 or Tet3) (15). Therefore, these findings suggested 
that the increase in the Tet activity might be accounted for by Tet1 up-regulation. Taken 
together, these results indicate that exposure to HDM may drive the Tet-mediated DNA 
hydroxymethylation in both the lungs and MASMCs, which may contribute to the 




Figure 1. Significant increases in 5hmC in HDM-exposed mouse lungs. Levels of 
5mC, 5hmC, 5fC, and 5caC were identified by immunohistochemical staining with the 
antibody specific for these 5C derivatives (scale bar=100 μm). Representative images of 
the lungs from each group are presented. The 5hmC levels were significantly increased 







Figure 2. Mice exposed chronically to HDM showed increased global and gene-
specific DNA hydroxymethylation, and increased Tet activity in the lung tissues. (A) 
Levels of 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) in the DNA 
samples from the blood, BALF cells, and isolated tracheal ASM cells (MASMCs) were 
detected via ELISA. The results are expressed as the mean values ± SEM, with 4-5 mice 
per group. (B) Enrichment of 5hmC on Tgfβ2, Smad2, and Smad3 were measured by 
qPCR. Hydroxymethylated DNA was immunoprecipitated with an antibody specific for 
5hmC. After reverse-crosslinking, the DNA was subjected to qPCR to examine the 
enrichment of 5hmC at the promoter region of the gene of interest. β-actin was applied as 
a housekeeping gene to normalize the amount of input DNA. The fold enrichment was 
determined as the ratio to the level of enrichment of 5hmC in the saline-exposed group. 
The results are expressed as the mean values ± SEM, with 3-4 mice per group. (C) TET 
activity was measured via ELISA, which measures the rate of conversion of 5mC to 
5hmC by Tet proteins. The results are the mean values ± SEM, with 4 or 3 mice per lung 
and mASMC group, respectively. For all comparisons, the unpaired t test was used, and 
































Tet1 Deficient Mice were protected from Acute HDM-induced AHR 
  
We sought to determine whether Tet1 up-regulation is associated with HDM-
induced AHR. First, 6-8 week-old male wild-type (WT) and heterozygous Tet1 deficient 
(Tet1+/-) mice were subjected to HDM challenges for the assessment of AHR phenotypes. 
The HDM exposure significantly increased the airway reactivity (~140%) to the MCh 
challenge at 30 µg/mL of MCh (Figure 3A) in the WT mice. In comparison, the TET1 
deficient mice exposed to HDM showed a significant decrease in airway reactivity to the 
MCh challenge. Next, we examined whether a Tet1 deficiency protected the tissues from 
the HDM-induced IgE production. Comparing the WT and Tet1+/- mice, the serum levels 
of IgE were unaffected by the loss of Tet1 in the acute HDM treated groups (Figure 3B). 
As expected, HDM exposure induced an inflammatory immune response by increasing 
eosinophils and lymphocytes, and decreasing the monocytes in the BALf in the WT mice 
(Figure 3C). In contrast, the TET1 deficiency did not result in a reduction in the HDM-
induced eosinophilia. However, the HDM-exposed Tet1+/- mice showed a slight reduction 
in the number of lymphocytes (not statistically significant). In addition, we examined the 
mRNA levels of the inflammatory mediators in the lung. The levels of Il4, Il13, and 
Foxp3 (but not Il5, Il10, and Muc5b) increased in both the WT and Tet1+/- mice exposed 















Figure 3. Tet1 deficiency reduced the acute HDM-induced airway hyper-
responsiveness (AHR), which might not affect the allergen sensitization to HDM and 
the development of a Th2 immune response. (A) Upper panel: Schematic picture 
depicting the HDM sensitization and challenges used in this study. Lower panel: 
Methacholine (MCh) was administered to the animals at increasing doses (0.1, 0.3, 1, 3, 
10, and 30 mg/mL) by a 10 second aerosol inhalation. AHR was assessed as the change 
in pulmonary resistance (R, cmH20/mL/s) compared to the baseline after the challenge to 
MCh. The results are expressed as the mean values ± SEM with 9-12 mice per group. 
black box: wild-type (WT) saline-exposed (n=12), black circle: WT HDM-exposed 
(n=11), blue diamond: Tet1+/- saline-exposed (n=10), blue box: Tet1+/- HDM-exposed 
(n=9). The two-way ANOVA with Bonferroni’s multiple comparisons test was used to 
determine the p values, which were *p<0.05 against the WT saline-exposed group, and ^ 
p<0.05 against the Tet1+/- HDM-exposed group.  (B) The expression level of the HDM-
specific IgE in the serum was measured via ELISA, and normalized to the total protein 
level. The results are expressed as the mean values ± SEM, with 6-9 mice per group. The 
one-way ANOVA with Tukey’s multiple comparisons tests was used, and statically 
significant comparisons were noted. (C) The total cell counts were measured in the 
BALF. The results were the mean values (x10^4) ± SEM, with 6-10 mice from each 
group, and presented next to the legends. WT saline-exposed (n=8), WT HDM-exposed 
(n=10), Tet1+/- saline-exposed (n=6), Tet1+/- HDM-exposed (n=6). Differential cell counts 
were obtained under a light microscope after staining the BAL cells with Hema-3 stain. 
The portion of the immune cells was calculated by the ratio in 400 cells counted per slide, 
multiplied by the total number of cells. The results were the mean values ± SEM, with 6-
7 mice from each group. WT saline-exposed (n=6), WT HDM-exposed (n=6), Tet1+/- 
saline-exposed (n=7), Tet1+/- HDM-exposed (n=6). The two-way ANOVA with Fisher’s 
LSD tests was used, and statically significant comparisons were noted. (D) The mRNA 
levels of the inflammatory mediators were assayed by qPCR. The results were the mean 
values ± SEM, with 5-6 mice from each group. The one-way ANOVA with Bonferroni’s 










Next, we investigated the effects of the Tet1 deficiency upon the pathological 
changes in the lungs from HDM exposure. First, H&E staining confirmed the findings 
from the differential cell count (Figure 3C), of increased immune cell infiltration into the 
lungs of the WT mice exposed to HDM, compared to those of the saline-exposed mice 
(Figure 4A). A slightly decreased cell infiltrate was shown in the HDM-exposed Tet1+/- 
mice. Second, Mason’s trichrome staining (MTS) revealed significant increases in the 
collagen deposition, especially around the airways, in the lungs of HDM-exposed WT 
mice. However, we did not observe a significant reduction in the collagen deposition in 
the lungs of the Tet1+/- mice exposed to HDM (Figure 4B). Finally, the HDM-exposed 
WT mice showed an increased number of goblet cells in the bronchial epithelium. The 
Tet1 deficient mice had slightly reduced the numbers of goblet cells and mucus formation 
(although not shown in the saline control groups), as shown by the Periodic Acid Schiff 
staining (Figure 4C). The histological assessment of the lung sections indicates that the 
loss of Tet1 activity caused a slight decrease in the HDM-induced airway inflammation.  
Overall, the loss of the Tet1 activity protected the mice from HDM-induced AHR, but it 
did not appear to affect the development of a Th2 immune response and allergen 
sensitization to HDM. Therefore, we proposed determining whether Tet1 regulates 
allergic AHR by altering the expression of the genes directly affecting ASM function.   
To further investigate the role of Tet1 in acute HDM-induced AHR phenotypes, we 
measured changes in the ASM phenotypic genes in both the lungs and MASMCs. The 
HDM-exposed WT mice showed increases in the mRNA levels of Ccnd1, Pcna (cell 
proliferation) Camk2D, and Mlck (cell contraction), but not Col1a and Col3a (collagen 
synthesis) in their lung tissues, compared to those of the WT saline control (Figure 5A). 
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Therefore, the Tet1 deficiency could completely prevent the HDM-induction of Pcna, and 
attenuate the two-fold induction of Mlck. When evaluating the ASM phenotypic genes in 
the MASMCs, the HDM-exposed WT mice showed a trend toward increased expressions 
of Pcna, Col3a and Col1a (although not statistically significant, p=0.08) (Figure 5B). 
The loss of Tet1 in HDM-exposed Tet1+/- mice completely prevented the HDM-induction 
of Pcna and Col1a but not Col3a. These date demonstrate that Tet1 deficiency provided 
protection from HDM-induced AHR by modulating the expression of genes related to the 




Figure 4. Tet1+/- deficient mice showed a slight decrease in the HDM-induced airway 
inflammation. The lung sections were stained with (A) Hematoxylin and Eosin (H&E) (scale bar 
= 100 μm), (B) Masson’s Trichrome Stain (MTS) (scale bar = 100 μm), and (C) Periodic acid-
Schiff (PAS) (scale bar = 50 μm). The representative images of the lungs from each group are 
presented. The arrows indicate (A) Increased inflammatory infiltration was observed near the 
airways of the WT HDM-exposed mice, with a slight decrease in the Tet1+/- HDM-exposed mice. 
(B) A slight decrease in collagen production (collagen fiber stained in blue) and (C) formation of 
goblet cells in the epithelium of the bronchus (stained in purple) in Tet1+/- HDM-exposed mice, 





Figure 5. Tet1 suppression prevented the HDM-induction of Pcna and Mlck in 
the lung tissues, and Pcna and Ccnd1 in the isolated ASMCs. The mRNA level of the 
ASM phenotypic genes (involved in cell proliferation and collagen synthesis) in the (A) 
lung tissues and (B) isolated ASMCs were measured by qPCR. The results were the mean 
values ± SEM (n=6 for lung tissues and n=3-6 for ASMCs per group). The one-way 
ANOVA with Bonferroni’s multiple comparisons tests were used, and statistically 
significant comparisons were noted.  
 
 
Loss of Tet1 modifies DNA Methylation Changes induced by HDM Exposure  
  
We further tested our hypothesis that Tet1 up-regulation contributes to allergic 
AHR through DNA methylation changes in the lung. We found no significant changes in 
the lung 5mC content among any of the treatment groups (Figure 6A).  But in the mouse 
ASMCs HDM exposure decreased the global 5mC content in both the WT and Tet1+/- 
mice (Figure 6A). Although, there was no change in 5mC content in the mouse ASMCs 
between the WT and Tet1 deficient mice exposed to HDM. In comparison, 5hmC content 
in mouse ASMCs decreased in Tet1 deficient mice exposed to HDM, compared to the 
WT-HDM group (Figure 6B). The results indicated that the Tet1 could modulate global 
changes in the DNA hydroxymethylation induced by HDM exposure in both the lung 
tissues and mouse ASMCs.  
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Figure 6. The Tet1 deficiency decreased the HDM-induced global DNA 
hydroxymethylation in the isolated ASM cells. The levels of (A) 5mC and (B) 5hmC in 
DNA samples from the lung tissues and isolated tracheal ASMCs were detected via 
ELISA. The results were the mean values ± SEM (n=3-6 for lung tissues and n=3 for 
ASMCs per group). The one-way ANOVA with Bonferroni’s multiple comparisons test 







In addition to the global changes in the DNA methylation and 
hydroxymethylation, we examined whether Tet1 up-regulation contributed to the HDM-
induced gene-specific DNA methylation changes in the mouse lungs and ASMCs. By 
utilizing genome-wide DNA methylation profiling techniques, our group identified 
differentially methylated candidates in the HDM-exposed mouse lung and ASMCs, and 
these changes were associated with an increased HDM-induced AHR (45). First, we 
examined the gene expression changes of these differentially methylated candidates in 
the mouse lung tissues (Table 2). The HDM-exposed WT mice showed a significant 
increase in mRNA level of Cartpt, Pde4d, Pom121l2, Smad3, and Tgfβ2. A non-
significant increase in Slc25a12 and Trpm2 (p=0.07) in these mice was also observed. 
The loss of Tet1 activity could completely reverse the HDM-induction of Pde4d, 
Slc25a12 and Trpm2. A 50% decrease in the Tgfβ2 expression was also found in the 
HDM-exposed Tet1+/- mice. We further examined whether the reduction of the Pde4d, 
Slc25a12, Tgfβ2 and Trpm2 were concomitant with the changes in their methylation 
status (Table 3). We found that the Tet1 deficiency reduced the HDM-induction of the 
Pde4d concomitant with increased Pde4d promoter methylation. In addition, the loss of 
Tet1 activity increased the Akt1s1 promoter methylation when compared to the WT mice, 





Next, we examined whether the loss of the Tet1 activity modulated the gene-
specific expression and methylation changes in ASMCs. In comparison, the ASMCs from 
the HDM-exposed WT mice showed increased transcript levels of Bmp3, Cartpt Pde4d, 
Smad3, Tgfβ2 and Trpm2 (Table 4). Interestingly, the Tet1 deficiency in the ASMCs 
almost completely blocked the HDM induction of the Bmp3, Cartpt, Smad3, Tgfβ2 and 
Trpm2. A 70% reduction in the HDM-induced Pde4d up-regulation was found in the 
HDM-exposed Tet1+/- mice. In addition, a decrease in the gene expression levels was 
shown in accordance with the increased DNA methylation status (Table 5). These results 
indicate that the loss of Tet1 activity can prevent the HDM induction of gene expression 



































Inhibition of TET1 modulates the Aberrant Cell Phenotypes in Asthmatics  
  
To assess potential clinical relevance, we investigated the epigenetic role of TET1 
in regulating the cell functions in human ASMCs. To determine whether TET1 
dysregulation resulted in altered ASM cell proliferative and contractile responses in 
asthmatics, we compared these ASM indices in ASMCs isolated from the deceased lung 
donations of non-asthmatics and asthmatics (Table 6).  Asthmatic ASMCs had increased 
gene expressions of CCND1 and PCNA (cell proliferation), CAMK2D (cell contraction), 
Col1A (collagen synthesis) and ADAM33, IL1B, SMAD2, SMAD3, TGFβ2 and VEGF 
(growth factors, cytokines, and mediators) compared to ASMCs from non-asthmatics 
(Table 7). These data suggest that asthmatic ASMCs can generate more collagens, growth 
factors, cytokines, and mediators that make the cells more proliferative and contractile 
than non-asthmatic ASMCs. Notably, the human asthmatic ASMCs showed several 







Furthermore, we showed that the ASMCs from the asthmatic donors had a 50% 
increase in the 5mC content and 80% increase in the 5hmC content (Figures 7A and 7B). 
In addition, the asthmatic ASMCs had twice the level of TET1 mRNA and TET activities 
when compared to those of the non-asthmatic ASMCs (Figures 7C and 7D).  
 
Figure 7. Asthmatic ASMCs showed increased 5mC, 5hmC, TET1 mRNA level, 
and TET activity compared to the non-asthmatic ASMCs. The levels of (A) 5mC and 
(B) 5hmC in the DNA samples isolated from the non-asthmatic and asthmatic ASMCs 
were detected using ELISA. (C) The mRNA levels of TET1 and (D) TET activity were 
measured by qPCR and ELISA, respectively. The results were the mean values ± SEM. 
With (A) n=5, (B) n=5, (C) n=6, and (D) n=8 donors from non-asthmatics and 
asthmatics. The unpaired t-test with Welch’s correction was performed, and statistically 




To directly determine whether the TET1-mediated epigenetic changes are 
associated with abnormal ASM cell function (increased ASM cell proliferation, 
contraction and collagen synthesis) in asthmatics, we utilized small interfering RNAs 
(siRNAs) against TET1 (siTET1) to target the knockdown of TET1 in both non-asthmatic 
and asthmatic ASMCs. siCTL was used as the non-target siRNA control in the siTET1 
transfection assay. We demonstrated that both siTET1 and siTET2 decreased TET1 and 
TET2 mRNA levels by more than 50%, respectively (Figures 8A and B), suggesting an 
effective siRNA knockdown in the ASMCs. The siTET1 and siTET2 decreased TET 
activity by 70% and 15%, respectively (Figure 8C). This suggests that the reduction in 
the TET activity was mainly due to TET1 in asthmatic ASMCs. To determine if TET1 
played a role in modulating cell proliferation, we measured the BrdU incorporation in the 
ASMCs upon siTET1 knockdown. As shown in other reports, the asthmatic ASM cells 
were more proliferative than the non-asthmatic ASMCs (Figure 8D). The knockdown of 
TET1 caused a decrease in the cell proliferation in asthmatic ASMCs when compared to 
the siCTL group. However, there was no significant effects seen in the non-asthmatic 
ASMCs. To further examine whether TET1 over-expression contributes to the aberrant 
phenotypes seen in asthmatics, we compared the expression levels of the ASM 
phenotypic genes by qPCR (Table 8) in the cells treated with siTETl.  
 
 In the asthmatic ASMCs, siTET1 decreased the PCNA, SMA (cell 
proliferation/mass), CAMK2D (cell contraction), ADAM33 and TGFΒ2 (growth factors) 
gene expressions when compared to the siCTL treatment. There were no significant 
differences in the ASM phenotypic gene expression in the non-asthmatic ASMCs treated 
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with siTET1. The absence of the silencing effect of the siTET1 on the ASM phenotypic 
genes in non-asthmatic ASMCs suggests that their respective ASM phenotypic genes 
may be at very low abundance. Taken together, these results indicate that TET1 depletion 
could reverse the elevated expression of the ASM phenotypic genes and cell proliferation 





Figure 8. siTET1 knockdown decreases TET1 expression and TET activity in 
ASMCs. The ASMCs were treated with lipofectamine (LF), non-targeting control siCTL, 
or siTET1 or siTET2 oligonucleotides for 3 days. The mRNA level of (A) TET1 and (B) 
TET2, and the (C) TET activity were measured by qPCR and ELISA, respectively. The 
results were expressed as the mean values ± SEM, with 5 non-asthmatic and 5 asthmatic 
donors. A two-way ANOVA with Tukey’s multiple comparisons tests was used, and 
statistically significant comparisons were noted. (D) The transfected cells were incubated 
with BrdU (5-bromo-2'-deoxyuridine) for 6 hours to allow the BrdU to be incorporated in 
place of thymidine into the newly synthesized DNA of the proliferating cells. The BrdU 
incorporation into the DNA was measured by colorimetric detection. The percent (%) 
BrdU incorporation was normalized to the LF control of the non-asthmatic ASMCs. The 
results were the mean values ± SEM, with 4 non-asthmatic donors and 4 asthmatic 
donors. The two-way ANOVA with Tukey’s multiple comparisons and statically 














In this study, we demonstrated that repeated exposures to common house 
allergens (HDM) in male mice increased the AHR and were associated with tissue/cell-
specific increased 5hmC and Tet activity in the lung and isolated mouse ASMCs. We 
further showed the Tet1 up-regulation in accordance with the increased gene-specific 
hydroxymethylation of Tgfβ2 (in both the mouse lungs and mouse ASMCs), Smad2 (lung 
tissues only) and Smad3 (MASMCs only), which consequently led to their increased gene 
expression levels (45). Given the fact that TET-mediated hydroxymethylation acts as the 
intermediate in the DNA demethylation pathway, we further examined the role of TET1 
in allergic AHR in cells from both mouse and human lungs. By utilizing a Tet1+/- mouse 
model, we demonstrated that the diminished activity of Tet1 protects mice from HDM-
induced AHR. Interestingly, comparing the WT and Tet1+/- mouse exposed to HDM the 
Tet1 deficiency had no effects on the HDM-induced neutrophilia, eosinophilia, and 
HDM-specific IgE production. We found that the Tet1 deficiency further increased the 
Foxp3 in the lungs of the mice exposed to HDM, compared to the HDM-exposed WT 
mice, indicating that Tet1 depletion promotes the Foxp3 transcription. FOXP3 (Forkhead 
box P3) is considered to be a master regulator for T-regulatory (Treg) cells (11, 84), and 
is often down-regulated in asthmatic patients, which showed increased FOXP3 promoter 
DNA methylation associated with its gene suppression and activation of Treg cells (11) 
that alleviate the airway inflammation. Future studies on how Tet1 regulates Foxp3 in 
mouse lungs could further improve the understanding of the epigenetic regulation of Treg 
cells in curing airway inflammation. Other than Foxp3, we did not find that Tet1 
deficiency results in the reduction of Th2 cytokine (Il4, Il5, and Il13) production, and 
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postulated that the protection from the HDM-induced AHR from the Tet1 deficiency was 
not attributable to modulations in the Th2 inflammatory immune response. Previous 
findings have indicated that the pathophysiology of AHR can occur independently from 
the inflammatory immune response (26, 85, 86). There have also been extensive studies 
into the epigenetic mechanisms of the inflammatory immune response in asthma.   
 
 The current understandings of epigenetic regulation in asthma mainly focus on the 
immune response involved in chronic airway inflammation, which is a hallmark of 
asthma pathogenesis (42, 69, 70, 87-90). Naïve CD4+ T cells differentiate into specific T 
helper cell subsets (Th1, Th2, Th17, and Treg), depending on the expression of the 
specific transcription factors (91). Asthma is generally considered to be a pro-
inflammatory Th2-driven disease in which an overexpression of Th2 cells drives asthma 
pathogenesis by secreting the pro-inflammatory cytokines IL4, IL5, and IL13. IL4 works 
in a positive feedback loop to increase CD4+ T cell differentiation into the Th2 lineage. 
Finally, the over-expression of Th2 cell activation exacerbates the risk of asthma by 
suppressing the production of the Th1 cells (70, 91).  Therefore, the epigenetic regulation 
of CD4+ T cell differentiation and T cell lineage maintenance in asthma has been widely 
studied. For example, Th2 cells express histone methylase SUV39H1, which 
trimethylates histone H3 on lysine 9 (H3K9me3) in key regulatory regions in Th1 genes, 
silencing the Th1 genes and maintaining the Th2 genes essential for Th2 differentiation 
and maintenance (91). Furthermore, the inhibition of SUV39H1 in an ovalbumin allergen 
induced asthma model showed an increased Th1 response and reduced allergic lung 
inflammation (91). These studies suggest that chromatin remodeling by histone 
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modification can skew the Th1/Th2 balance toward a Th2 allergic inflammation 
phenotype. In addition to histone modifications, DNA methylation has been found to 
regulate the Th1/Th2 imbalance in experimental asthma models.  
An ovalbumin challenge increased the DNA methylation of the Ifng promoter, and 
was associated with an increased Th2 driven inflammatory immune response. The 
inhibition of DNA methylation with 5-aza-2-deoxycytidine resulted in the demethylation 
of the Ifng promoter, and protected the mice from ovalbumin induced airway 
inflammation (92). In the case of adult monozygotic twins, one with asthma and one 
without, the asthmatic twin showed impaired Treg activity that was associated with 
increased DNA methylation in the promoter region of FOXP3, and decreased FOXP3 
gene and protein expression (11). In addition, serum B-lymphocytes from HDM-allergic 
asthmatic subjects were globally hypermethylated, compared to those of the non-
asthmatic controls (93). The HDM-allergic asthmatics also showed an increase in the IL4 
receptor gene expression in B lymphocytes, which supports the idea of increased IL4 
signaling and the B lymphocyte activation implicated in the immune dysregulation of 
asthma (94). There have been extensive studies into the epigenetic mechanisms of the 
inflammatory immune response in asthma, because they can be performed on the easily 
accessible inflammatory cells. Our results indicated that the epigenetic regulation of 
airway reactivity by Tet1 occurs mainly in the ASM cells. This may support the previous 
findings that the pathophysiology of AHR can occur independently from the 
inflammatory immune response (26, 85, 86).   
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 We demonstrated that TET1 plays an important role in global and gene-specific 
methylation changes, specifically in ASM cells. Given the fact that epigenetic changes 
are cell and tissue-specific, different tissues might have unique 5mC and 5hmC profiles 
that can be altered through the induction of TET activity (52, 95) upon various exposures 
to environmental pollutants or chemicals. Our findings indicate that HDM challenges 
may induce TET1 up-regulation and its mediated DNA hydroxymethylation, specifically 
in ASMCs, and alter cell functions through the epigenetic gene regulation of ASM 
phenotypic genes. In addition to inflammatory cells, the ASMCs lining the airway lumen 
are largely implicated in asthma pathogenesis through aberrant ASM function, structure, 
or inflammatory response, which result in the increased wheezing and shortness of breath 
associated with asthma (85). Aberrant ASM functions, such as increased contraction or 
bronchoconstriction, and decreased relaxation contribute to airway narrowing, while 
increased ASM mass, basement membrane thickening, and mucus gland hyperplasia are 
implicated in the structural changes of airway remodeling and ASM synthesis. The 
release of IL5, IL13, and TGFβ cytokines in ASMCs further propels airway inflammation 
(85, 96-98). Our findings reiterate that the epigenetic role of TET1-mediated DNA 
hydroxymethylation as a cell-specific response to environmental stimuli is able to 
modulate the development of asthma phenotypes. Thus, there is great potential for the 
design of epigenetic therapies targeted toward TET1-mediated asthma pathogenesis (69, 
99). Traditionally, beta-agonists are the most commonly used therapy for treating asthma, 
by which the beta2-adrenergic receptor (β2-AR) is activated to increase cyclic adenosine 
monophosphate (cAMP) production, which activates protein kinase A (PKA), and 
subsequently relaxes the ASM through the inhibition of myosin light chain kinase 
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(MLCK) (97). Nevertheless, the downside to therapy using beta-agonists for ASM 
relaxation is that prolonged use can lead to tachyphylaxis, or the loss of β2-AR 
expression that causes desensitization to the agonist and inability to control 
bronchoconstriction. Our data demonstrated a novel role for the specific 5mC 
dioxygenase, TET1, in regulating ASM function in vitro and in the development of 
allergen-driven AHR in vivo. It provides considerable new insights into the role of the 
ASM in the development of AHR, and the development of modulators of this critical 
pathway to ameliorate allergen-induced AHR and asthma.   
 
 We were able to translate our experimental asthma model to human asthmatic 
ASM cells by demonstrating that TET1 up-regulation is a generalized phenomenon in 
ASMCs for individuals with asthma. A heterogeneous population of lung donors with 
unknown exposures or allergic profiles may expect inter-individual epigenetic variations. 
Nevertheless, we were able to confirm the generalized role of increased 5hmC, TET1 
expression, and TET activity in ASMCs from individuals with asthma when compared to 
non-asthmatics. There were discrepancies between the 5mC levels, which were 
unchanged in the MASMCs of the HDM-exposed mice, but increased in human 
asthmatic ASMCs. The differences in the global 5mC levels comparing mouse and 
human ASMCs could be due to species differences in the overall CpG contents as well as 
disparate exposures over varying periods; with human asthmatic ASMCs exposed to 
complex mixtures of environmental agents over decades of disease progression. Despite 
these differences, the knockdown of TET1 by siTET1 in human asthmatic ASMCs could 
modulate the aberrant ASM phenotypic gene expression and cell proliferation, similar to 
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the loss of Tet activity upon the regulation of ASM genes and AHR in our Tet1+/- mouse 
model. To our knowledge, this study is the first to investigate the role of Tet1-mediated 
DNA hydroxymethylation associated with altered AHR phenotypes. Given the reversible 
nature of epigenetic changes in the cells, our data may provide insights into the 
development of modulators of this critical pathway to ameliorate allergen-induced AHR 
and asthma.  
 
 There is great potential for the design of epigenetic therapies targeted toward 
TET1-mediated asthma pathogenesis, particularly in regulating ASM functions. 
Traditionally, beta-agonists are the most commonly used medication for treating asthma 
by activating the beta2-adrenergic receptor (β2-AR) to increase cyclic adenosine 
monophosphate (cAMP) production, which in turn activates protein kinase A (PKA) and 
subsequently relaxes the ASM through the inhibition of myosin light chain kinase 
(MLCK) (97). Nevertheless, the downside to using beta-agonists for ASM relaxation is 
that prolonged use can lead to tachyphylaxis, or the loss of β2-AR expression that causes 
desensitization to the agonist and inability to control bronchoconstriction (83, 97). 
Moreover, epigenetic regulation of ASMCs has been shown to have therapeutic potential 
in asthma treatment (42, 44, 100, 101). Recently, we have demonstrated that the 
suppression of PDE4D gene expression in asthmatic ASMCs, through CpG site specific 
methylation at the PDE4D promoter with methylated oligonucleotides, could abrogate 
the ASMC phenotypes seen in asthmatics (102). Additionally, the administration of the 
histone deacetylase inhibitor, valproic acid, was shown to protect mice from ovalbumin-
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induced AHR and airway remodeling, indicating the potential for histone modulators in 
the treatment of asthma (66).     
 
 There are limitations in our current study. First, we have not presented the role of 
TET1 in airway remodeling commonly seen human asthmatics, because our HDM-
induced AHR mouse model only demonstrated the acute effects of allergens on airway 
reactivity and inflammation. To address these concerns in the future, the use of chronic 
HDM exposure upon the Tet1 deficient mice may better capitulate the effects of lifelong 
exposure to allergens and AHR. We speculate that chronic repeated exposures to HDM 
could further exacerbate the HDM-driven AHR by modulating ASM remodeling via 
aberrant epigenetic changes in the ASM cells, at least partly through TET-mediated 
hydroxymethylation. Second, Tet1 homozygous mice (Tet1-/-) were not employed in our 
AHR model. Previous investigations revealed that the embryonic loss of Tet1 is not 
lethal, but that it produces Tet1–/– offspring with significantly reduced body size, weight, 
and fertility (79). Therefore, due to the fertility limitations and runt phenotypes, Tet1–/– 
were less abundant and more susceptible to pre-mature death, which is why we opted to 
compare the effects of acute HDM between Tet1+/+ and Tet1+/– mice. Despite the use of 
Tet1+/- mice, the loss of only one allele was adequate to see significant phenotypic 
changes in the lung function. Therefore, we would expect that chronic HDM exposure 
would further increase the HDM-induced airway resistance, measured by AHR, and that 
the deficiency in Tet1 (Tet1+/-) would create a larger reduction in the HDM-induced 
AHR, and an even more substantial reduction with the complete loss of Tet1 (Tet1-/-), 
given that the mice survived the chronic HDM challenge regimen. In addition, our mouse 
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model used a whole body knockout of Tet1, which could have unforeseen implications 
upon our HDM-induced AHR findings in the lung and isolated MASMCs.  
 
Tet1 suppression does not acutely regulate allergen-driven IgE or eosinophilia, 
suggesting that Tet1 deficiency may not influence the acute airway inflammation 
response; however, Tet1 may play a role in chronic airway inflammation and the 
development of AHR. To further the understanding of the role of Tet1 depletion in 
immune cells, epithelial cells, and ASM cells upon HDM-induced AHR, tissue-specific 
knockout studies of Tet1 could be employed. Furthermore, it is questionable whether 
Tet1 up-regulation only occurs upon HDM exposure in the mouse. However, this is 
unlikely because we demonstrated that TET1 up-regulation is a generalized phenomenon 
seen in human asthmatics. This is an ideal illustration of chronic and varied 
environmental exposures leading to increased AHR. We can postulate that the effects of 
allergens on Tet1 in our mouse model will also been seen with other allergens or 
environmental exposures. Future studies can test whether TET1 up-regulation in human 
asthmatics is influenced by environmental exposures, allergen sensitivities, severity of 
disease, or medication use in a well-defined human asthmatic population. 
In summary, our results provide a novel perspective of the epigenetic regulation 
of allergen-driven changes in ASM function and AHR. We directly address gaps in our 
understanding of how environmental insults may initiate asthma. These findings also 
introduce the novel concept that TET1 modulators might induce bronchodilation or 
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CHAPTER 3 
THE ROLE OF OXIDATIVE STRESS 
UPON TET1 REGULATION IN 







































The significance of DNA methylation in modulating gene expression changes and 
biological mechanisms has been implicated in many diseases. Currently, oxidation of 5-
methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) by ten-eleven 
translocation (TET) enzymes, considered an intermediate in the DNA demethylation 
pathway, has renovated previous concepts of epigenetic regulation. Previously, we 
demonstrated that Tet1 deficiency protected mice from allergen-induced airway 
hyperresponsiveness, a cardinal feature of asthma. Further, we demonstrated that TET1 
up-regulation contributed to the aberrant airway smooth muscle cell (ASMC) phenotypes 
seen in the clinical features of asthma. Therefore, by understanding the mechanisms of 
TET1 regulation in human airway smooth muscle cells (ASMCs), we can gain insight 
into the aberrant ASMC phenotypes implicated in the pathological outcomes of asthma. 
Changes in oxidant balance are proposed to trigger the production of alpha-ketoglutarate 
(alpha-KG), which can activate TET enzymes and potentially disrupt cellular and 
biological processes. We aimed to investigate if oxidant balance modulates the regulation 
of TET enzymes, especially TET1, in the ASMCs from non-asthmatic and asthmatic 
patients. We found that transforming growth factor, beta 1 (TGFβ1) increased oxidative 
stress in ASMCs, which in turn increased citrate metabolism gene IDH2 and alpha-KG 
production, as well as up-regulated TET activity and cell proliferation in non-asthmatic 
cells. By contrast, Sulforaphane (SFN) treatment abrogated oxidative stress levels and 
reduced alpha-KG metabolite levels that corresponded with decreased TET activity in 
both non-asthmatic and asthmatic cells. Furthermore, SFN reduced cell proliferation 
phenotypes and cell proliferation genes (PCNA, CCND1, and TGFβ2) in addition to cell 
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contraction genes (MYLK2 and CAMK2D) in both non-asthmatic and asthmatic ASMCs. 
In summary, we demonstrated that modulation of oxidant balance can alter the generation 
of alpha-KG metabolite pools and subsequently regulate TET activity and ASM cell 
phenotypes. Our findings suggest a therapeutic potential of anti-oxidants to modulate 





The ability of DNA methylation, the most commonly studied epigenetic 
mechanism, to modify gene regulation and biological mechanisms generated considerable 
research interest on the DNA methylation patterns associated with disease mechanisms. 
The discovery of ten-eleven translocation (TET) proteins, which alter DNA methylation 
profiles by catalyzing the oxidation of 5-methylcytosine (5mC) into 5-
hydroxymethylcytosine (5hmC), an intermediate in the DNA demethylation pathway, has 
completely changed the epigenetic landscape. Therefore, understanding the DNA 
methylation machinery involved in DNA hydroxymethylation profiles, in addition to 
DNA methylation changes, gives considerable insight into the epigenetic modifications 
possibly implicated in disease mechanisms. For example, in Alzheimer’s disease patients, 
post-mortem hippocampus brain tissue exhibited decreased 5hmC content as the disease 
pathology advanced with increased hippocampal amyloid plaques and neurofibrillary 
tangles (103). In melanoma cancers, the 5hmC content decreased depending on the 
progression of the tumor with high 5hmC content in benign melanocytic nevi and a 
significant decrease in primary and metastatic melanomas that correlated with decreased 
TET1, TET2, and TET3 gene expression compared with the nevus control (104). Aberrant 
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DNA hydroxymethylation has been shown to influence asthma pathogenesis (42). In 
Chapter 2, we demonstrated in an allergen-induced model of airway hyperresponsiveness 
(AHR) that the loss of TET1 decreased 5hmC levels and was associated with decreased 
AHR in mouse lungs. Furthermore, we also reported that TET activity and its mediated 
hydroxymethylation could alter changes in ASM phenotypic genes in both mouse and 
human ASMCs.  
 
The co-factors involved in DNA hydroxymethylation are thought to be critical to 
the activation of TET proteins. TET proteins are 2-oxoglutarate-dependent dioxygenases 
that require co-factors, such as iron(II) (Fe2+), oxygen, and 2-oxoglutarate (alpha-KG), 
for the oxidation of 5mC into 5hmC. Recent evidence has supported the idea of TET 
activity enhancement through ascorbic acid (AA) or vitamin C (105-107). AA can 
uniquely interact with the C-terminal catalytic domain of TET enzymes to promote their 
folding and/or recycling of the cofactor Fe2+(105). Aside from Fe2+, alpha-KG is another 
co-factor that regulates TET activity. In the first step of the citric acid cycle, citrate 
synthase combines acetyl-coA with oxaloacetate for the irreversible formation of citrate, 
which is converted to isocitrate by the aconitase enzyme (108). Isocitrate dehydrogenase 
enzymes (IDH1, IDH2, and IDH3) subsequently convert isocitrate into alpha-KG, an 
intermediate in the citric acid cycle and the required co-factor for TET activity (109). In 
mouse embryonic stem cells, the addition of cell-permeable alpha-KG in the medium 
increased intracellular alpha-KG levels and decreased overall DNA methylation profiles; 
it is also associated with the increased expression of inner cell mass and germline 
associated genes (Wdfc15a, Asz1, and Dazl) (110). These results indicate that increased 
alpha-KG metabolites up-regulate TET-mediated DNA demethylation pathways to 
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decrease global DNA methylation, as well as the gene-specific hypomethylation of 
Wdfc15a, Asz1, and Dazl to increase gene expression. In a zebrafish melanoma model, 
the overexpression of IDH2 increased 5hmC content and prolonged the tumor-free 
survival of zebrafish with small and less invasive tumors compared with the control 
(104). The overexpression of IDH2 activity increased the generation of alpha-KG and up-
regulated the TET-mediated 5hmC content, which protected zebrafish from aggressive 
melanocytic metastasis and death. Imbalances in the oxidant and antioxidant homeostasis 
have been hypothesized to modify the production of alpha-KG. Under high oxidative 
stress conditions, increased nicotinamide adenine nucleotide (NAD) levels in the 
mitochondria activate sirtuin NAD+ -dependent deacetylases (SIRT) (111). Activation of 
SIRT3 results in the deacetylation of IDHs, which in turn increases IDH1 and IDH2 
activity, as well as the subsequent activation of citrate metabolism for increased alpha-
KG production (112, 113), which facilitates the activation of TET. For example, the in 
vivo administration of glucose in mice exhibited increased alpha-KG metabolite levels in 
liver tissue that corresponded with increased TET-mediated 5hmC content in the liver 
(114). Therefore, oxidative stress imbalances can affect citrate metabolism by altering 
SIRT and IDH activity, and it also affects the production of alpha-KG metabolite levels 
that are sensitively linked to the regulation of TET activity.  
 
Increased oxidative stress has been shown to underlie the disease mechanisms 
among asthmatic patients (14, 115-117). Furthermore, chronic exposures to air pollution, 
pollen, or environmental tobacco smoke have been shown to increase reactive oxygen 
species (ROS) production, which plays a role in the induction of airway inflammation 
and remodeling in the lungs (118-120). In the airways, a relentless and complex 
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interaction of oxidative stress occurs from external sources inhaled through the 
environment and internal sources from the inflammatory immune response (115). 
Although the airways are under assault with every breath, many anti-oxidant mechanisms 
mitigate the ROS imbalances in the airways. Exposures to air pollution, pollen, or 
environmental tobacco smoke result in inflammatory cell recruitment, activation of 
NADPH oxidases, and epithelial cell mitochondrial dysfunction, which generate the toxic 
anion superoxide (O2
._) that can be neutralized by scavenger super oxide dismutase 
enzymes into hydrogen peroxide (H2O2) and oxygen (O2) (115, 121). In peroxisomes, 
catalase degrades H2O2 into water (H2O) and oxygen (O2). Also, glutathione peroxidase 
degrades H2O2 into water by reducing glutathione (GSH) into oxidized glutathione-
disulfide, which can be converted back to GSH by glutathione reductase. At any step 
along this process, any residual or excess superoxide and H2O2 can interact with 
macromolecules (DNA, lipids, protein) in the cell to exhibit oxidative damage and inflict 
airway oxidative stress. Substantial increases in ROS production may damage the airway 
epithelium to facilitate the increased presentation of allergen/pathogenic substances to 
airway dendritic cells and other inflammatory cells and further activate the secretion of 
pro-inflammatory cytokines and chemokines (122). These inflammatory mediators can 
further modulate the functions of the resident cells in the airway and lead to the 
development of airway remodeling. 
 
 Taken together, strong evidence indicates that an imbalance in redox cycling 
fosters increased airway oxidative stress in asthma. Herein, we hypothesize that increased 
ROS production in the lungs facilitates increased alpha-KG production and the 
subsequent TET activation and then ultimately modulates lung function. We already 
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demonstrated the significant role of TET1 in human ASMCs in Chapter 2, so we now 
investigate if altered intracellular ROS levels can trigger citrate metabolism changes to 
modulate alpha-KG production and TET activity in human ASMCs. Furthermore, we will 
determine whether this proposed mechanism can reverse the aberrant cell phenotypes 




Cell culture  
Human ASM cells were derived from the tracheas of deceased non-asthmatic and 
asthmatic donors from the National Disease Research Interchange (Philadelphia, PA), as 
previously described (83). Donor characteristics (age, gender, race, history) are described 
in Table 1. Cells were received at passage 3 and maintained in DMEM/F-12 medium 
(Corning Cellgro, Manassas, VA) supplemented with 10% FBS (Invitrogen, Carlsbad, 
CA), 1% Penicillin-Streptomyocin Solution (Corning Cellgro, Manassas, VA), and 1% L-
Glutamine (Corning Cellgro, Manassas, VA). Cells were not used once they reached 
passage 12.  
 
Drugs treatment 
Human ASM cells were treated with either 30 μM DL-Sulforaphane (SFN) (Sigma-
Aldrich, St. Louis, MO) or 1 ng/mL human TGFβ1 (R&D Systems, Minneapolis, MN) 
for the desired time point. 
  
Measurement of reactive oxygen species (ROS) production 
Human ASM cells were grown in 96-well black plates for 2 days before the cells were 
incubated with 50 μM of 2’,7’- Dichhlorofluorescein diacetate (DCFDA) (Sigma Aldrich, 
St. Louis, MO) for 1 hour. After DCFDA incubation, the cells were treated with either 30 
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μM SFN, 1 ng/mL TGFβ1, or a range of hydrogen peroxide (0–1000 μM as a positive 
control to measure ROS production). At the desired time points (3, 6, and 24 hours), ROS 
was detected by the formation of 2’,7’- Dichhlorofluorescein to measure ROS production 
(425 nm/emission 530 nm). 
 
Cell viability measurement 
Trypan Blue Solution (Corning Cellgro, Manassas, VA) was used to distinguish viable 
and non-viable cells after drug treatment.  
 
Cell proliferation measurement  
At a desired time after drug treatment, the cells were incubated with 5-bromo-2'-
deoxyuridine (BrdU) solution for 6 hours, according to the BrdU Cell Proliferation Assay 
Kit (Cell Signaling, Beverly, MA). Briefly, BrdU analog incorporation into DNA was 
fixed and denatured before the BrdU detection antibody was added for 1 hour. Secondary 
HRP-linked antibody was added and incubated for 0.5 hour. Tetramethylbenzidine 
substrate was added to develop color. Color formation was measured at an absorbance of 
450 nm.  
 
Assessment of mRNA level 
Total RNA (1 μg) isolated from human ASM cells by TRIzol (Invitrogen, Carlsbad, CA) 
was reverse transcribed with iScript Reverse Transcriptase (Bio-Rad, Hercules, CA). 
Gene transcript levels were quantified by SYBR Green-based or TaqMan-based real-time 
PCR. The 2-ΔΔCt method was used to calculate the relative expression level of transcripts 






Alpha- Ketoglutarate (alpha-KG) assay 
At a desired time after drug treatment, the cells were collected, and the cell number was 
counted. With the use of a Dounce homogenizer on ice cold alpha-KG assay buffer, 
3x10^6 cells were homogenized before the samples were processed according to the 
alpha-KG Assay Kit (Sigma Aldrich, St. Louis, MO). The colorimetric detection of 
alpha-KG at 570 nm was plotted against a standard curve to determine the alpha-KG 
concentration.  
 
Assessment of TET activity  
Nuclear protein extracts were isolated from cells with the use of EpiQuick Nuclear 
Extraction Kit (Epigentek, Farmingdale, NY). Proteins were quantified for total protein 
levels (Pierce BCA Protein Assay Kit, ThermoScientific, Rockford, IL). To measure TET 
activity, 2–6 μg of total nuclear protein was used (Epigentek, Farmingdale, NY). TET 
activity was assayed with the use of Epigenase 5mC Hydroxylase TET 
Activity/Inhibition Kit (Epigentek, Farmingdale, NY). In brief, TET substrate was added 
to all wells and incubated at 37 °C for 1.5 hours. Then, nuclear proteins were incubated 
with TET substrate at 37 °C for 1.5 hours to convert the TET substrate into 5hmC 
product. Capture antibody was added to recognize the TET-converted products, and then 
detection antibody was added. Finally, the colorimetric conversion of the developer 
solution was measured at 405/655 nm, and TET activity was calculated compared with 
standards.  
 
Sulforaphane (SFN) exposure in mice and AHR measurement 
Adult male C57BL/6J mice, 6 to 8 weeks old, were obtained from Jackson Laboratories 
(Bar Harbor, ME). All mice were housed under controlled lighting (12 hours light and 12 
hours dark) and temperature (21–22 °C) conditions. The mice were housed in 
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polysulfone-ventilated cages (Technoplast, Exton, PA) and provided with Harlan’s 
Teklad Global 18% Protein Extruded Rodent Diet 2018SX and fresh water ad libitum. 
Male mice, at 6 to 8 weeks of age, were sensitized on day 0 (treatment day) with 50 μg of 
house dust mite (HDM) extract (D.Pteronyssinus, Greer Laboratories, Lenoir, NC) 
(diluted in 200 μL PBS) or saline (PBS) intraperitoneally (i.p.). Two weeks after (day 
14), the mice were challenged with 50 μg of HDM (diluted in 50 μL PBS) or PBS 
(intratracheally, i.t.) twice on days 14 and 21. Another group of mice was exposed to 50 
mg of SFN (diluted in 200 μL PBS) i.p. on days 1, 3, and 5 after the first HDM 
sensitization. The mice were further challenged by HDM i.t. twice on days 14 and 21. 
Pulmonary function test for AHR was measured on day 23. The SFN and HDM exposure 
protocol is depicted in a schematic in Figure 7. The mice were anesthetized i.p. with 
pharmaceutical-grade ketamine and xylazine. After approximately 15 minutes, a 20-
gauge IV catheter was placed in the trachea and secured with a suture. The mice were 
maintained on a mechanical ventilator that delivers a constant inspiratory flow of air. The 
mice were administrated with increasing doses of aerosolized Methacholine chloride 
(Mch) (Sigma-Aldrich, St. Louis, MO) (0.1, 0.3, 1, 3, 10, and 30 mg/mL) while 
maintained on the ventilator. Mch challenge was followed by airway resistance 
measurement by flexiVent (SCIREQ, Montreal, Canada). AHR was assessed as the 
change in pulmonary resistance (R cm/H2O/mL/s) compared with the baseline after the 
Mch challenge. Lung tissues were harvested and subject for alpha-KG and TET activity 






Statistical analysis  
Results were expressed as mean ± standard error mean. Student t-test was used to analyze 
the differences in ASM characteristics between non-asthmatic and asthmatic ASM cells. 
For group comparison, two-way ANOVA of multiple comparisons with Bonferroni’s and 
Tukey’s corrected tests was applied to determine if the data between treatment groups 
was statistically significant. The details of the statistical analysis are described in each 
data figure and table. All data were analyzed and plotted with Prism6 (GraphPad, La 
Jolla, CA).  
 
Study approval 
All experimental procedures used in this study were approved by the Institutional Animal 
Care and Use Committee of Johns Hopkins University (Baltimore, MD) (MO14H241). 
Human ASMCs from non-asthmatics and asthmatics were either purchased from a 
commercial vendor (Lonza, Gaithersburg, MD) or obtained from deceased donors in 
accordance with the Institutional Review Board of the University of Pennsylvania and 






Oxidant levels in ASMCs can modulate ASM cell phenotypes  
 
We demonstrated the role of increased oxidative stress in asthmatic ASMCs, 
which is well reported in asthmatic patients (122, 123). All ASMC donors were adults, 
with an even mix of males and females, although most were Caucasian (Table 2). 
Examining their history, we found that both non-asthmatics and asthmatics generally 
reported no tobacco use, and most non-asthmatics died from head traumas, whereas most 
asthmatic ASMC donors died from a fatal asthma attack (Table 2). Given the 
heterogeneous ASMC donor characteristics, we first determined if asthmatic ASMCs had 
higher basal ROS levels than the non-asthmatics. ROS level was measured by the 
production of DCFDA, an indicator of oxidative stress, in cells over 24 hours (Figure 1). 
A significant increase in ROS levels in asthmatic ASMCs was evident compared with 
non-asthmatics at 3 and 6 hours, although not statistically significant at 24 hours (Figure 
1). We observed that the ROS level at 24 hours was approximately double the level at 6 
hours in both non-asthmatic and asthmatic ASMCs (Figure 1). Overall asthmatic ASMCs 
trended towards higher ROS levels than non-asthmatics. Together, our results indicate 





Figure 1. Asthmatic ASMCs have increased ROS production. Basal levels of non-
asthmatic and asthmatic ROS levels were measured by the relative fluorescence units 
(RFU) measured at Excitation 425nm/Emission 530nm in the DCFDA assay at 3, 6 and 
24 hours. Results expressed as mean values ± SEM, with 5 non-asthmatic and 5 asthmatic 
donors per group. Multiple t-test comparisons were used to determine the p-value and 











To test the effects of oxidant balance alterations on ASMCs, we exposed ASMCs 
to TGFβ1 or SFN and examined the phenotypic changes of non-asthmatic and asthmatic 
cells. In all the subsequent experiments on ASMCs, the data for each ASMC donor were 
calculated as a ratio compared with the average of the non-asthmatic control (untreated) 
group. The average of the non-asthmatic control was set at 100%. We decided to express 
the data in this manner, so we could detect the significant changes in each assay, which 
can be obscured if expressed as raw values because of the baseline noise attributed to the 
heterogeneity of the non-asthmatic and asthmatic donors. For example, at 24 hours, a 
25% increase in ROS production was observed in asthmatic ASMCs compared with non-
asthmatics (Figure 2A). Similarly, at 3 hours, asthmatic ASMCs had ~40% more ROS 
than non-asthmatic ASMCs (Figure 2B). These results confirm our previous findings of 
increased basal ROS level in asthmatic ASMCs (Figure 1). TGFβ1 is a pleiotropic 
cytokine that plays many roles in the lung through complex TGFβ signaling pathways 
that have effects on cell apoptosis, proliferation, and angiogenesis. The TGFβ pathway 
also influences biological processes in endothelial cells, goblet cells, fibroblasts, and 
ASMCs (124, 125), and ultimately contribute to the development of airway remodeling. 
Treatment with TGFβ1 increased ROS levels in both non-asthmatic and asthmatic cells 
by 25% and 10%, respectively (Figure 2A). Notably, TGFβ1 treatment induced the ROS 
levels in non-asthmatic cells to the ROS levels shown in the asthmatic controls. In 
contrast, treatment with the antioxidant SFN for 3 hours decreased the ROS levels by 
30% in asthmatic ASMCs, but it had no effect in non-asthmatic cells (Figure 2B). These 
results indicated that the ROS levels in ASMCs could be modulated by TGFβ1 and SFN.  
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Figure 2. TGFβ1 increased ROS production and SFN decreased ROS 
production. DCFDA assay was used to measure ROS production after (A) treatment 
with TGFβ1 at 1ng/mL for 24 hours and (B) with Sulforaphane (SFN) at 30uM for 3 
hours. Relative change of ROS production in each group was normalized to the average 
of the non-asthmatic control (CTL) group.  Results expressed as mean values ± SEM, 
with 4 non-asthmatic and 5 asthmatic donors per group.  Two-way ANOVA with 
Bonferroni’s multiple comparisons tests was used and statistically significant 





Next, we sought to determine if the modification of ROS levels corresponded to 
alterations in ASMC phenotypes, such as cell viability and cell proliferation (Figure 3). 
At baseline, the number of viable cells between non-asthmatic and asthmatic ASMCs was 
not different (Figure 3A and B, left panel). But at baseline, measurement of the BrdU 
incorporation in cells indicated that asthmatic ASMCs showed increased cell proliferation 
(>50%) compared with non-asthmatics (Figure 3A and B, right panel). This finding 
suggests that asthmatic ASMCs are more proliferative than non-asthmatic cells, a 
characteristic that is commonly demonstrated in asthmatic patients (98). TGFβ1 caused a 
non-statistically significant increase (p=0.06) in the number of viable cells in non-
asthmatics but not in the asthmatic group (Figure 3A, left panel). Using the BrdU assay, 
we demonstrated that TGFβ1 increased the cell proliferation of non-asthmatic ASMCs by 
30% (Figure 3A, right panel). The result suggests that TGFβ1 treatment in non-asthmatic 
ASMCs not only increased the number of viable cells but also drove them toward a 
proliferative phenotype. Surprisingly, TGFβ1 slightly decreased the cell proliferation of 
asthmatic ASMCs by 20%, as measured by the BrdU assay. On the other hand, exposure 
to SFN decreased both the number of viable cells and cell proliferation in both non-
asthmatic and asthmatic ASMCs (Figure 3B). SFN decreased non-asthmatic ASM cell 
number and cell proliferation by 30% and 70%, respectively (Figure 3B). In asthmatic 
ASMCs, SFN decreased the cell number by 50% and reduced cell proliferation by 140% 
(Figure 3B). The reduction of cell proliferation by SFN in asthmatic ASMCs was larger 
than that in non-asthmatic cells, and indicates that SFN has a very compelling anti-
proliferative property in ASMCs from patients with asthma. SFN is a potent inducer of 
nuclear factor erythroid-2 related factor-2 (NRF2) activation, which is a critical 
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transcription factor for antioxidant response elements located in the promoter of anti-
oxidative stress and phase II detoxifying genes (126). In asthmatic ASMCs, NRF2 
activity is usually at a very low level (30), and we may speculate that SFN exposure may 
boost up NRF2 activity and induce a dramatic increase in the transcription of genes 





 Figure 3. TGFβ1 increased cell proliferation and SFN decreased cell 
proliferation. BrdU incorporation and Trypan Blue cell viability assays were used to 
examine the cell proliferation and cell viability after (A) treatment with TGFβ1 at 
1ng/mL for 48 hours and (B) with Sulforaphane (SFN) at 30uM for 24 hours (BrdU 
incorporation assay) or 48 hours (Trypan Blue cell viability assay). Relative changes in 
BrdU incorporation and cell viability were normalized to the average of the non-
asthmatic control (CTL) group.  Results expressed as mean values ± SEM. BrdU 
incorporation on TGFβ1 treatment, 4 non-asthmatic and 4 asthmatic donors. Trypan Blue 
cell viability assay on TGFβ1 treatment, 3 non-asthmatic and 3 asthmatic donors. BrdU 
incorporation on SFN treatment, 4 non-asthmatic and 2 asthmatic donors. Trypan Blue 
cell viability assay on SFN treatment, 3 non-asthmatic and 6 asthmatic donors.  Two-way 
ANOVA with Bonferroni’s multiple comparisons tests were used and statistically 
significant comparisons were noted. 
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In addition to the increased cell proliferation, increased cell contraction, synthesis 
of collagen, and growth factors were measured since they are considered to be aberrant 
ASMC phenotypes contributing to airway remodeling and AHR. We measured the 
changes in mRNA level of ASM phenotypic genes (cell proliferation, CCND1 and 
PCNA; collagen synthesis, COL3A; cell contraction, CAMK2D and MYLK2; and growth 
factors/mediators, ADAM33 and TGFβ2) after 48 hours of TGFβ1 (Table 3) and SFN 
(Table 4) treatment. Treatment of TGFβ1 did not change the expression of CCND1 and 
PCNA in non-asthmatic or asthmatic ASMCs (Table 3). However, TGFβ1 increased the 
gene expression of COL3A by 100% in non-asthmatic ASMCs (Table 3). Asthmatic 
ASMCs also showed a 70% increase in COL3A expression with TGFβ1 treatment (Table 
3). This finding suggests that TGFβ1 may facilitate collagen synthesis in ASMCs. 
Exposure to TGFβ1 caused a three-fold increase in MYLK2 expression in non-asthmatic 
cells and a nine-fold increase in MYLK2 expression in asthmatic cells (Table 3), which 
indicates the role of TGFβ1 in increasing ASM cell contraction. Unexpectedly, TGFβ1 
decreased CAMK2D expression in both the non-asthmatic and asthmatic cells (Table 3). 
ASM cells can generate mediators and growth factors. TGFβ1 treatment induced a four-
fold increase in TGFβ2 expression and suppressed ADAM33 expression by half to a level 
comparable to baseline asthmatic ASMCs (Table 3). Taken together, these results 
indicate that TGFβ1 can drive gene expression changes in non-asthmatic cells to be more 
contractile and proliferative similar to asthmatics ASMCs.  
 
In response to SFN (Table 4), CCND1 expression was reduced by 78% and 319% 
in non-asthmatic and asthmatic ASMCs, respectively. Similarly, SFN treatment 
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decreased PCNA expression by 68% in non-asthmatic ASMCs and by 98% in asthmatic 
ASMCs (Table 4). This result suggests that SFN can inhibit cell proliferation (seen in 
Figure 3B) by decreasing the gene expression of CCND1 and PCNA. Moreover, a 
significant decrease in COL3A expression in SFN-treated asthmatic ASMCs was 
observed (Table 4). Non-asthmatic ASMCs also showed a decreasing trend in COL3A 
expression in response to SFN, although the change was not statistically significant 
(p=0.08) (Table 4). The results indicated that SFN might suppress collagen synthesis in 
ASMCs. In addition, SFN decreased genes associated with ASM cell contraction. SFN 
treatment decreased CAMK2D (90% and 77%) and MYLK2 (84% and 78%) in both non-
asthmatic and asthmatic ASMCs, respectively (Table 4). For ASM cell growth factors 
and mediators, SFN reduced ADAM33 and TGFβ2 expression by 56% and 89%, 
respectively, in asthmatic ASM cells only (Table 4). To summarize, SFN, by decreasing 
the expression of ASM phenotypic genes to levels that are comparable to that of non-
asthmatics, may reverse the aberrant cell phenotypes seen in asthmatics ASMCs. 
Consistent with the anti-proliferative effects of SFN, we observed a larger change in the 
reduction of ASM phenotypic gene expression levels in asthmatic ASMCs than in non-
asthmatic ASM cells. Furthermore, we demonstrated that the modulation of ROS levels 
might either drive non-asthmatic ASMCs toward aberrant cell phenotypes seen in 









Alterations in citrate metabolism via NAD+-dependent redox cycling associated with 
TET activity 
 
Next, we sought to investigate the effects of oxidative stress on TET activation by 
measuring the production of alpha-KG and the key factors involved in isocitrate 
metabolism (Figure 4). At baseline, asthmatic ASMCs showed increased mRNA levels of 
sirtuin NAD+-dependent deacetylases (SIRT1 and SIRT3) and isocitrate dehyogenase 
(IDH2) (Figure 4A and B) compared with non-asthmatic ASMCs. This result suggests 
the asthmatic ASMCs may have increased citrate metabolism compared with non-
asthmatic ASMCs. First, we determined if increased ROS by TGFβ1 can alter alpha-KG 
production. We found that TGFβ1 had no effect on SIRT1, SIRT3, and IDH1 in non-
asthmatic or asthmatic ASMCs (Figure 4A and B). However, in non-asthmatic ASMCs, 
TGFβ1 did increase IDH2 mRNA level by 80%, a level close to that of untreated 
asthmatic ASMCs (Figure 4B). TGFβ1 also caused an additional induction of IDH2 
(~300%) in asthmatic ASMCs (Figure 4B). In addition, the level of alpha-KG was 
increased by 70% in non-asthmatic ASMCs and no effect in asthmatic cells (Figure 4C). 
Consequently, the increased alpha-KG level in non-asthmatic ASMCs was associated 
with a 40% increase in TET activity (Figure 4D). Taken together, these findings indicated 
that TGFβ1 increased IDH2 gene expression and subsequent alpha-KG production to up-
regulate TET activity in ASMCs. Notably, TGFβ1 increased IDH2-mediated alpha-KG 
production and TET activity in non-asthmatic ASMCs to a level equivalent to that of 
untreated asthmatic ASMCs.  
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      Figure 4. TGFβ1 increased IDH2 mRNA level and increased alpha-KG level and 
TET activity in non-asthmatic ASM cells. Cells harvested at 48 hours after TGFβ1 
(1ng/mL) were subject to the measurement of (A) NAD-dependent deacetylase sirtuins 
(SIRT1/2) mRNA  (B) Isocitrate dehydrogenase (IDH1/2) mRNA (C) alpha-
ketoglutarate (alpha-KG) and (D) TET activity. (A and B)  mRNA levels of SIRT1, 
SIRT2, IDH1 and IDH2 were measured by qPCR. Relative Expression Ratio (RER) 
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values were calculated by 2-ddCt method, where the RER was set as 1.00 in the non-
asthmatic control (CTL) group. Results expressed as mean values ± SEM, with 6 non-
asthmatic and 4 asthmatic donors. Two-way ANOVA with Bonferroni’s multiple 
comparisons tests was used and statistically significant comparisons were noted. (C) 
alpha-KG level was measured by alpha-KG enzymatic assay kit. Relative change of 
alpha-KG production was normalized to the average of alpha-KG production of the non-
asthmatic control (CTL) group. Results expressed as mean values ± SEM, with 3 non-
asthmatic and 2 asthmatic donors per group. Two-way ANOVA with Bonferroni’s 
multiple comparisons tests was used and statistically significant comparisons were noted. 
(D) TET activity was measured by ELISA. Relative change of TET activity in treated 
group was normalized to the TET activity of the non-asthmatic control (CTL) group. 
Results expressed as mean values ± SEM, with 4 non-asthmatic and 3 asthmatic donors 



















Second, we investigated if the reduction of ROS levels by SFN can decrease TET 
activity via NAD+-dependent alpha-KG production. SFN treatment dramatically 
decreased (>60%) the expression of citrate metabolism genes, SIRT1 and SIRT3, in 
asthmatic ASMCs to levels below those of the non-asthmatic and asthmatic controls 
(Figure 5A). In addition, IDH1 and IDH2 were down-regulated (>50%) in both non-
asthmatic and asthmatic ASMCs treated with SFN (Figure 5B). In response to SFN, the 
IDH2 mRNA levels in asthmatic ASMCs were reduced to levels comparable with those 
of non-asthmatic controls (Figure 5B). Furthermore, we showed that the reduction in 
SIRT1, SIRT3, IDH1, and IDH2 mRNA levels was associated with decreased alpha-KG 
production and TET activity. SFN decreased alpha-KG levels in non-asthmatic and 
asthmatic ASMCs by 25% and 35%, respectively (Figure 5C). Consequently, we 
demonstrated that SFN can reduce TET activity in non-asthmatic and asthmatic ASMCs 
by 60% and 55%, respectively (Figure 5D). Therefore, our data suggested that SFN 
decreased citrate metabolism (SIRT1, SIRT3, IDH1, and IDH2) to abrogate alpha-KG 
levels. Decreased alpha-KG resulted in the reduction of TET activity. To summarize, 
although the increased ROS levels induced by TGFβ1 had no effect on NAD+-dependent 
deacetylases (SIRT1 and SIRT3), it did correlate well with increased IDH2-mediated 
alpha-KG production and TET activity in non-asthmatic ASMCs. By contrast, the 
decreased ROS levels by SFN comprehensively decreased citrate metabolism (SIRT1, 
SIRT3, IDH1, and IDH2) and accompanied diminished alpha-KG production and TET 
activity in both non-asthmatic and asthmatic ASMCs. The results suggest that 
intracellular alpha-KG levels are critical to modulating TET activity, and alpha-KG 
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production is ROS dependent. We summarized our findings in a schematic diagram 
shown in Figure 6. 
 
Figure 5. SFN decreased SIRT1, SIRT3, IDH1, IDH2 mRNA level, alpha-KG 
level and TET activity in asthmatic ASM cells. Cells harvested at 48 hours after 
exposure of Sulforaphane (SFN) (30uM) were subject to measurement of  (A) NAD-
 112 
dependent deacetylase sirtuins (SIRT1/2) mRNA level, (B) Isocitrate dehydrogenase 
(IDH1/2) mRNA levels and (D) TET activity. (C) Assay for alpha-ketoglutarate (alpha-
KG) level was performed at 24 hours after the SFN exposure. (A and B) mRNA levels of 
SIRT1, SIRT3, IDH1 and IDH2 were measured by qPCR. Relative Expression Ratio 
(RER) values were calculated by 2-ddCt method, where the RER was set as 1.00 in the 
non-asthmatic control (CTL) group. Results expressed as mean values ± SEM, with 4-6 
non-asthmatic and 4-6 asthmatic donors per group. Two-way ANOVA with Bonferroni’s 
multiple comparisons tests was used and statistically significant comparisons were noted. 
(C) alpha-KG level was measured by alpha-KG enzymatic assay kit and the percentage 
of alpha-KG levels were calculated compared to the average of the non-asthmatic control 
(CTL) group. Relative change of alpha-KG production was normalized to the average of 
alpha-KG production of the non-asthmatic control (CTL) group. Results expressed as 
mean values ± SEM, with 3 non-asthmatic and 3 asthmatic donors per group. Two-way 
ANOVA with Bonferroni’s multiple comparisons tests was used and statistically 
significant comparisons were noted. (D) TET activity was measured by ELISA. Relative 
change of TET activity in treated group was normalized to the TET activity of the non-
asthmatic control (CTL) group. Results are expressed as mean values ± SEM, with 3 non-
asthmatic and 3 asthmatic donors per group. Two-way ANOVA with Bonferroni’s 





Figure 6. Proposed role of oxidative stress upon citrate metabolism and TET 
activity.  Increased reactive oxygen species (ROS) in human ASM cells may affect 
NAD+ cycling, which in turn activates the NAD-dependent deacetylase sirtuins 
(SIRT1/SIRT2) and Isocitrate Dehydrogenase (IDH1/IDH2) activity to increase the 
conversion of isocitrate to alpha-KG; a citrate metabolism intermediate. The resulting 
increased alpha-KG production, a cofactor for TET1, promotes TET1 enzymatic activity 
and the oxidation of 5mC to 5hmC. Our results indicated that modulation of ROS by 
TGFβ1 or Sulforaphane could modulate the level of ROS production, which in turn alters 












Can oxidative stress alter epigenetic mechanisms other than TET1? 
 
In addition to altered TET activity in ASMCs, changes in oxidant levels may 
trigger other DNA methylation machinery. In DNA methylation, DNMT1 maintains CpG 
methylation during replication, whereas both MBD1 and MECP2 are methyl-CpG 
binding domain (MBD) proteins that bind methylated DNA and act as transcriptional 
repressors. Both TET1 and TET2 are involved in DNA hydroxymethylation, an 
intermediate in the DNA demethylation pathway that requires DNA repair enzymes, such 
as AID, MBD4, and TDG. DNA deaminase AID removes an amino group from 5hmC to 
form 5-hydroxymethyluracil (5hmU), and DNA glycosylase enzymes MBD4 and TDG 
mediate the removal of thymine, uracil, and 5-fluorouracil in G:T and G:U mismatched 
base pairs to generate the correct G:C base pairs. We investigated the gene expression of 
epigenetic modulators in ASMCs treated with TGFβ1 (Table 5). At baseline, asthmatic 
ASMCs showed significantly increased mRNA levels of MBD1 and TDG compared with 
non-asthmatic ASMCs (Table 5). Asthmatic ASMCs also showed increased expression of 
MBD4, TET1, and TET2 and decreased expression of DNMT1, although the changes were 
not statistically significant (Table 5). No significant changes in DNMT1, MBD1, and 
MECP2 in non-asthmatic and asthmatic ASMCs treated with TGFβ1 were observed. In 
non-asthmatic ASMCs, TGFβ1 treatment markedly increased MBD4 (50%), TET1 
(100%), and TET2 (50%) expression to a level comparable to that of untreated asthmatic 
controls (Table 5). Also, a 90% increase in AID expression (although it was not 
statistically significant, p=0.059) was observed in non-asthmatic ASMCs treated with 
TGFβ1 (Table 5). Only TDG showed further increase by 190% in asthmatic ASMCs after 
exposure to TGFβ1 (Table 5). In summary, the results indicated that TGFβ1 modulates 
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the expression of enzymes involved in DNA demethylation machinery (AID, TDG, 
MBD4, TET1, and TET2) in non-asthmatic cells. How these methylation changes link to 
aberrant ASMC phenotypes requires further investigation.  
 
Next, we sought to determine if the reduction of ROS levels modified the gene 
expression levels of DNA methylation/demethylation modulators (Table 6). No 
significant changes were observed in DNMT1, MBD1, MECP2, TDG, and TET2 in non-
asthmatic ASMCs treated with SFN (Table 6). By contrast, SFN significantly decreased 
MBD4 and TET1 expression, whereas it increased AID expression in both non-asthmatic 
and asthmatic ASMCs (Table 6). Only in asthmatic ASMCs did SFN decrease MBD1 and 
TET2 expression by 90% and 107%, respectively (Table 6). No significant changes in 
TDG expression were found in asthmatic ASMCs exposed to SFN (Table 6). To 
summarize, suppression of ROS levels by SFN can modulate the expression of genes 
involved in DNA demethylation (MBD4, TET1, and AID) in both non-asthmatic and 
asthmatic ASMCs. In addition, MBD1 and TET2 in asthmatic ASMCs were responsive to 
SFN treatment. Notably, SFN can reverse the aberrant epigenetic changes (at least DNA 
methylation machinery) in asthmatic ASMCs. How these methylation changes link to 






Sulforaphane pre-treatment protects mice from HDM-induced AHR 
 
Finally, we explored a potential therapeutic strategy of targeting TET activity by 
administering antioxidants to relieve airway hyperresponsiveness (AHR) in an allergic 
AHR model. We investigated the in vivo effects of SFN upon HDM-induced AHR. 
HDM-exposed mice that were administered SFN showed decreased induction of airway 
resistance toward 10–30 mg/mL Mch by 40%–50% compared with the HDM-exposed 
mice, a result indicating that SFN exposures protected the mice from HDM-induced AHR 
(Figure 7A). In addition, SFN exposures can completely reverse the induction of alpha-
KG production (Figure 7B) and TET activity (Figure 7C) by HDM in the mouse lung. 
Therefore, in vivo, we confirmed our findings from the human ASMCs that the 
suppression of ROS levels can decrease AHR phenotypes by modulation of alpha-KG 
production and TET activity.    
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 Figure 7. Sulforaphane treatment protects mice from HDM-induced AHR. 
(A) Upper panel: Schematic picture depicting the HDM sensitization and challenges used 
in this study. Lower panel: Methacholine (Mch) was administered to the animals at 
increasing doses (0.1, 0.3, 1, 3, 10, 30 mg/mL) by a 10 second aerosol inhalation.  AHR 
was assessed as the change in pulmonary resistance (R, cm H20/mL/s) compared to 
baseline after the challenge to Mch. Results are expressed as mean values ± SEM with 4 
mice per group; black box: Saline-exposed, grey box: HDM-exposed, triangle: 
HDM+SFN-exposed.  Two-way ANOVA with Bonferroni’s multiple comparisons test 
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was used to determine the p value, which were *p<0.05 vs Saline-exposed group; and ^ 
p<0.05 against HDM+SFN-exposed group. (B) alpha-ketoglutarate (alpha-KG) levels in 
lung tissue were measured by the alpha-KG enzymatic assay. Results expressed as mean 
values ± SEM, with 4 animals per group.  One-way ANOVA with Bonferroni’s multiple 
comparisons tests was used and statistically significant comparisons were noted. (C) TET 
activity was measured by ELISA. Results are expressed as mean values ± SEM, with 4 
animals per group. One-way ANOVA with Bonferroni’s multiple comparisons tests were 
























Understanding TET1 regulation provides strategies to reverse the aberrant 
phenotypes of asthmatic ASMCs 
 
In this study, we demonstrated that modulation of oxidant balance can alter TET 
activity and its-mediated ASMC phenotypes. As reported in other studies, increased 
oxidative stress has been shown to be associated with the increased airway inflammation 
and reactivity of asthmatic patients (9–12). Increased oxidative stress in asthma patients 
affects many cells in the airways. For example, ROS production has been reported from 
epithelial, type II alveolar, endothelial, and smooth muscle cells in the airways generated 
from mitochondrial stress, NADPH enzymes, and inflammatory cells (121). In ASM 
cells, the oxidative stress burden is mostly attributed to increased NOX4 expression in 
asthmatics, which is correlated with the increased ASMC contraction mitigated in the 
presence of NOX4 inhibitors (123, 127). In addition, human asthmatic ASMCs exhibited 
decreased nuclear factor (erythroid-derived 2)-like 2 (NRF2) binding to the antioxidant 
response element (ARE), as well as decreased heme oxygenase (HO)-1 mRNA and 
protein levels, the primary anti-oxidant defense pathway activated from NRF2 activation, 
compared with non-asthmatic controls (128). These results indicate the repressive role of 
anti-oxidant defense mechanisms in asthmatic ASMCs. Therefore, modulating the 
oxidant balance in ASMCs can play a part in the regulation of ASMC phenotypes 
observed in asthma pathogenesis. Our current findings support this idea by demonstrating 
the effect of TGFβ1 and SFN on ASMCs. Furthermore, we showed that the regulation of 
ASMC phenotypes by ROS is facilitated at least partly thorough epigenetic 
modifications. We used TGFβ1 and SFN as a pro-oxidant and anti-oxidant, respectively, 
to modulate the levels of oxidative stress in ASMCs. We showed that TGFβ1 and SFN 
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had opposing effects on modifying ROS levels in the human ASMCs model. TGFβ1 is 
considered an immunomodulator in asthma pathogenesis and can lead to adverse effects 
in animal models of asthma as both a potent suppressor of inflammation, as well as an 
inducer of AHR with increased fibrosis, inflammation, and airway remodeling (129). In 
addition, TGFβ1 induced gene expression of activating transcription factor (ATF3), an 
NRF2 repressor, whereas it decreased the gene expression of HO-1 in human ASMCs 
(128). These previous studies validate our current findings that TGFβ1 increased ROS 
levels, possibly through the repression of NRF2 activation and subsequent decrease in 
phase II enzymes. Moreover, TGFβ1 is continually up-regulated in asthmatic patients and 
has physiologic relevance to airway remodeling in asthma pathogenesis (125). On the 
other hand, SFN is a phytochemical abundant in broccoli extracts and is a potent inducer 
of endogenous phase II detoxification enzymes that scavenge reactive oxygen species to 
mitigate oxidative stress and maintain oxidative homeostasis (130).  
 
We showed that TGFβ1 induced the proliferative phenotypes in ASMCs, whereas 
SFN suppressed the aberrant ASMC phenotypes seen in asthmatics. We and others have 
shown that asthmatic ASMCs proliferate more, contract more, and synthesize collagen 
more than non-asthmatic ASM cells (102). In addition, we reported that asthmatic 
ASMCs have increased ROS levels compared to non-asthmatic cells (Figure 2). Thus, we 
examined whether increased ROS levesl by TGFβ1 in non-asthmatic cells can induce 
phenotypic changes in non-asthmatic ASM cells to resemble asthmatic ASMCs and vice 
versa with SFN treatment on asthmatic ASMCs to reverse the aberrant ASMC phenotype. 
We found that TGFβ1 increased cell proliferation in non-asthmatic cells, while SFN 
treatment decreased cell proliferation in both non-asthmatic and asthmatic cells, 
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measured by the BrdU incorporation assay (Figure 3A). Furthermore, we demonstrated 
that molecular changes are linked with aberrant ASM phenotypes by measuring the 
expression of genes related to cell proliferation, cell contraction, and synthesis of 
collagen, growth factors, and mediators in ASMCs. Exposure to TGFβ1 in non-asthmatic 
ASMCs induced the expression of COL3A, MYLK2, and TGFβ2, a result suggesting that 
TGFβ1 may drive non-asthmatic ASMCs to produce collagen, contract more, and grow 
faster than asthmatic ASMCs.  
 
By contrast, reduction of ROS level by SFN reduced cell proliferation (Figure 3B) 
in both non-asthmatic and asthmatic ASMCs. Moreover, SFN decreased the expression 
of genes involved in cell proliferation (CCND1, PCNA, and TGFβ2), collagen synthesis 
(COL3A), and cell contraction (CAMK2D and MYLK2) in asthmatic ASMCs. Our results 
are consistent with previous in vitro investigations in human ASMCs that reported SFN 
induced NRF2 protein expression and ARE activation to reduce ASMC proliferation 
(128). Our findings indicated that SFN can possibly reverse the asthmatic ASMC 
phenotypes and induce asthmatic cells to appear phenotypically non-asthmatic. Most 
impressive, we found that asthmatic ASMCs treated with SFN had a significant reduction 
in cell proliferation and expression of ASM phenotypic genes to levels below the baseline 
of untreated non-asthmatic ASMCs. This result might be due to the fact that NRF2 
activity or other NRF2-signaling pathways in asthmatic ASMCs are susceptible in 
response to antioxidant defense, such as SFN exposure. However, the significant 
suppressive effects of SFN upon cell proliferation could also be related to the dose of 
SFN exposure.  
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Moreover, the effects of SFN treatment on modulating ASM-related phenotypes 
were corroborated with our in vivo model demonstrating that SFN exposure can reduce 
allergic–AHR and is associated with a decrease in TET activity in mouse lungs (Figure 
7). In addition, we showed that SFN exposure can reverse the induction of TET activity 
in asthmatic ASMCs (Figure 5). Given the fact that inhibition of TET1 can reverse the 
aberrant ASM cell phenotypes and HDM-induced AHR (Chapter 2), our present findings 
support the use of SFN to reduce airway oxidative stress in the therapeutic treatment of 
asthma. Indeed, clinical studies have shown that the administration of oral SFN in 
broccoli sprout extract homogenate induced phase II enzymes glutathione-s-transferase 
M1 (GSTM1), glutathione-s-transferase P1 (GSTP1), NADPH quinone oxidoreductase 
(NQO1), and hemoxygenase-1 (HO-1) in the upper airway of human subjects compared 
with the controls, who ingested alfalfa sprouts, measured by qPCR analysis in nasal 
lavage cells (130). Additionally, oral broccoli sprout extract consumption in allergic 
asthma subjects for four days attenuated the induction of total cell counts in the nasal 
lavage after diesel exhaust particle challenge (131). Taken together, these results support 
the therapeutic and nutritional value of SFN consumption to ameliorate oxidative stress in 
the lungs. Although the therapeutic potential of SFN treatment in airway inflammation 
has already been investigated, our study is the first to associate SFN with decreased 
alpha-KG production and decreased TET enzymatic activity, especially in ASMCs that 
can suppress asthmatic ASMC phenotypes.  
 
Novel role of ROS in citrate metabolism and subsequent TET activity of ASMCs 
 
We identified a novel role of ROS in regulating epigenetic modifications via 
alterations in citrate metabolism. Our asthmatic ASMCs had increased TET activity and 
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ROS levels, a result suggesting that TET activity in ASMCs is likely regulated through 
oxidative stress pathway. We hypothesized that the oxidative stress level regulates citrate 
metabolism to modify alpha-KG production and subsequently activate TET enzymes. All 
TET proteins (TET1-3) contain catalytic domains at their carbonyl-terminus, which 
consist of both a cysteine-rich region and dioxygenase, which converts 5mC into 5hmC, 
with the use of Fe2+ and alpha-KG. Under oxidative stress conditions, the level of NAD+ 
was increased in the mitochondria, which can activate the SIRT family of protein 
deacetylases, which in turn deacetylate IDH2 to promote IDH2 activity (20, 132). We 
demonstrated that TGFβ1 increased alpha-KG production and TET activity in non-
asthmatic ASMCs. Only IDH2 gene expression was increased, and no significant effects 
were found on SIRT1, SIRT3, and IDH1 gene expression (Figure 4). These findings 
suggest that induction of alpha-KG production and TET activity by TGFβ1 may be 
dependent on IDH2 activity. Further experiments will be performed to examine the link 
between TGFβ1-induced ROS production and IDH2-mediated alpha-KG production. 
Nonetheless, our findings indicate the possible role of ROS production in TET up-
regulation in asthmatics (summarized in Figure 6).  
 
In addition, we demonstrated that SFN significantly decreased the gene 
expression of SIRT1, SIRT3, IDH1, and IDH2, which subsequently reduced intracellular 
alpha-KG level and TET activity in both non-asthmatic and asthmatic ASMCs (Figure 5). 
Furthermore, these findings support our hypothesis that SFN may apply as an epigenetic 
modifier to suppress TET activity and reverse the TET1-mediated expression of ASM 
phenotypic genes reported earlier. In this study, we focused on the effect of ROS on 
alpha-KG production given the fact that we found up-regulation of SIRT1, SIRT3, IDH1, 
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and IDH2 in asthmatic ASMCs. Nevertheless, modulation of Fe2+ level by ascorbic acid 
was shown to enhance TET activity (133). Low plasma levels of ascorbic acid have also 
been reported to be associated with increased asthma risk. However, the link between 
ascorbic acid and TET-mediated asthma pathogenesis has not yet been identified. As a 
first step, we demonstrated that ascorbic acid did not alter TET activity in ASMCs, a 
result suggesting that the mechanisms underlying TET regulation may be tissue or cell 
specific. Also, since TET proteins are 2-Oxoglutarate-dependent-oxygenases that require 
2-Oxoglutarate (alpha-KG) to convert 5mC to 5hmC (52, 134) , we further provided the 
evidence that alpha-KG plays a critical role in regulating TET enzymes in ASMCs.  
 
ROS may also mediate epigenetic changes via TET-independent mechanisms, 
such as DNA or histone methylation that can be modulated by GSH depletion (135, 136). 
Therefore, we investigated the roles of other epigenetic modulators involved in DNA 
methylation machinery in modifying epigenetic changes in ASMCs in response to 
oxidative stress. TGFβ1 induced the gene expression of TET1, TET2, AID, MBD4, and 
TDG (DNA hydroxymethylation and DNA repair-mediated demethylation) in non-
asthmatic ASMCs that might contribute to the aberrant alterations in ASM phenotypic 
gene expression and ASM phenotypes. No significant changes in the expression of 
modulators responsible for DNA methylation were observed (DNMT1, MBD1, and 
MECP2). These results suggest that increased ROS by TGFβ1 may promote DNA 
demethylation/hydroxymethylation rather than suppress DNA methylation machinery. 
They are also consistent with our previous findings that exposures to allergen induced a 
profile of demethylated candidates in mouse lung (45).  
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Asthmatic ASMCs, in response to SFN, showed a decreased expression of TET1, 
TET2, and MBD4 (DNA hydroxymethylation and DNA repair-mediated demethylation). 
These results provide evidence that a reduction of ROS levels by SFN suppressed DNA 
hydroxymethylation and demethylation. By contrast, SFN exposure induced MECP2 
expression in ASMCs, a result suggesting that SFN may facilitate DNA methylation. 
Although we have not identified any gene-specific changes associated with changes in 
the expression of these epigenetic modulators, these preliminary findings provide a 
general understanding of the role of ROS in epigenetic regulation. The use of SFN has 
been shown to modulate a wide range of epigenetic modifications, including the 
hypomethylation of the NRF2 promoter, decreased DNMT1 and DNMT3A protein 
levels, and decreased HDAC1,4,5,6 protein levels, which improve prostate cancer 
treatment (126). Altogether, our investigation into the alterations of epigenetic 
modulators in response to TGFβ1 and SFN provides insight into the mechanisms 
underlying epigenetic modulation of ASM phenotypes and subsequent AHR phenotypes. 
Moreover, it provides possible therapeutic tools to target the ROS-dependent citrate 
metabolism enzymes and TET1-mediated DNA hydroxymethylation. 
 
Citrate metabolism and DNA methylation in ASMCs 
 
In this study, we showed the effect of ROS on alpha-KG production and its 
subsequent TET activation in ASMCs. We demonstrated that oxidative stress modulated 
the generation of alpha-KG from isocitrate by SIRTs and IDH. During glycolysis, 
glucose is converted to pyruvate, which is in turn converted to acetyl-CoA by the 
pyruvate dehydrogenase complex in an oxidative process in which NADH and CO2 are 
formed. Acetyl-CoA enters the Krebs cycle when it converts to citrate and subsequently 
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to isocitrate and alpha-KG. Alternatively, glycolysis also generates serine, an essential 
amino acid and precursor for purine and pyrimidine biosynthesis (137). Serine not only 
provides the methyl groups critical to the synthesis of DNA nucleotides but also 
contributes methyl groups to the increased formation of S-adenosylmethionine (SAM) 
substrates, which are the required methyl donors for DNMT enzymes to maintain DNA 
methylation (137). Increased serine production generates alpha-KG as a by-product of the 
phosphoserine aminotransferase reaction (137). Therefore, the generation of alpha-KG 
metabolite pools occurs through diverse metabolic regulation pathways and can alter 
epigenetic profiles through increased TET or DNMT activity. For example, in cancer 
cells, the increased glucose uptake is metabolically reprogrammed, often called the 
Warburg effect, to divert from the citric acid cycle, and it instead increases in serine 
metabolism to promote anabolism and proliferation, which increases the SAM and alpha-
KG metabolite levels to alter DNA methylation via DNMTs and TETs. These results 
indicate that intracellular pools of metabolites, such as alpha-KG, can have important 
implications on the regulation of many epigenetic modulators implicated in disease 
phenotypes.  
 
In the present study, we have not shown that alpha-KG production is dependent 
on isocitrate metabolism because the generation of alpha-KG production in cells can be 
done in many ways. In the future, we aim to confirm that the changes in alpha-KG 
production from TGFβ1 and SFN exposure are mediated through citrate metabolism 
pathways by suppression of IDH activity. Moreover, which oxidative stress defense 
pathways modulate the alpha-KG metabolite levels in ASMCs will also be examined. 
Our current study reported the global associations between alpha-KG production and 
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increased TET1 activity. Further investigations on the gene-specific changes in DNA 
methylation and hydroxymethylation through ROS-dependent TET activity are 
warranted. Finally, to convincingly prove that TET1 is modified through oxidative stress 
to change ASMC phenotypes, we plan to determine if the repression and induction of 
TET1 activity in ASMCs can modulate the cell proliferation phenotypes. In conclusion, 
our results suggest, for the first time, the association between oxidative stress level and 
alpha-KG production, which in turn alters TET activity and modifies ASM phenotypic 
gene expression and ASMC phenotypes in relation to asthma pathogenesis. Notably, the 
anti-oxidant effects of SFN significantly reduced oxidative stress-mediated alpha-KG 
production, diminished the proliferative phenotypes of ASMCs, and reduced AHR 
phenotypes in vivo. Our findings not only improve our understanding of epigenetic 
regulation in asthma pathogenesis but also provide insight into the design for epigenetic 
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4.1 Tet1-mediated DNA hydroxymethylation regulates allergic-induced airway 
hyperresponsiveness  
 
The rise in the prevalence of asthma has increased the need for innovative 
research to understand the complex mechanisms underlying asthma pathogenesis.  More 
comprehensive understanding of asthma etiology will improve prospective novel and 
effective therapeutic treatments.  Given that asthma pathogenesis involves a gene-by-
environment interaction, epigenetic mechanisms likely contribute to asthmatic disease.  
Therefore, unraveling the underlying epigenetic code contributing to asthma pathogenesis 
can highlight distinct epigenetic mechanisms responsible for aberrant biological 
pathways in asthma.  Since epigenetic changes in the genome are reversible increased 
epigenetic research offers a tremendous therapeutic opportunity to target these unique 
mechanisms and possibly reverse or modify gene expression regulation and the 
pathogenesis of asthma.   
 
Chronic HDM challenges in C57B6 mice increased airway hyperresponsiveness 
(AHR) that corresponded with increased Tet activity and 5hmC product in mouse lungs 
and airway smooth muscle cells (ASMCs). Thereafter, we hypothesized that Tet1-
mediated hydroxymethylation contributes to allergen-induced AHR through epigenetic 
regulation of lung cells function.  Using a heterozygous Tet1 deficient (Tet1+/-) mouse 
model, we demonstrated that the loss of Tet1 protected mice from allergic AHR.  
Furthermore,  Tet1 deficiency significantly reduced the HDM-induced global 5hmC 
content in both the lung and ASMCs.  Additionally, the loss of Tet1 activity 
corresponded with the reversal of the HDM-induced gene expression of AHR-related 
genes in both the lung and ASMCs. Overall, these findings depict a novel role of Tet1 
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and its-mediated DNA hydroxymethylation upon global epigenetic regulation in the lung 
and tissue specific changes in ASMCs in response to environmental exposures to house 
allergen.  To enhance our understanding of the role of ASM in asthma pathogenesis, we 
have to further investigate the role of aberrant ASM epigenetic regulation in regards to 
lung function by depleting Tet1 specifically in mouse ASMCs, with a tissue-specific Tet1 
knockout mouse model. Also, it would be interesting to evaluate the Tet1-mediated 
epigenetic changes in the development of the inflammatory immune response with HDM-
exposure, especially with repeated exposures to HDM.  Hence, we envisioned using the 
Tet1 deficient mouse model to improve our understanding of asthma pathogenesis 
through identifying the role of environmental perturbations upon lung function 
phenotypes and epigenetic changes in the lung as well as in the diverse cell types 
involved in asthma pathogenesis; ASMCs, epithelial cells, and immune cells.  
 
4.2 Targeting Tet1 activity could be applied for preventive or therapeutic 
approaches for treating asthma  
 
In addition to the demonstration on the role of Tet1-mediated DNA 
hydroxymethylation in mouse AHR, we further confirmed the hypotheses generated in 
mouse systems in primary human asthmatic ASM cells.  Certainly, asthma pathogenesis 
is complex with heterogeneous changes induced in the whole lung. While the changes 
that others and we have identified to date in the immune cell types are important and 
likely reflect changes in the airway inflammatory status of patients, few studies have 
examined epigenetic changes directly in airway resident cells like ASMCs. ASM 
remodeling (increased ASM mass and collagen synthesis by ASM) together with 
enhanced ASM contractility has been suggested to play an important role in AHR either 
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dependently or independently of airway inflammation. Therefore, we narrowed our focus 
on the epigenetic regulation of human ASMCs from non-asthmatic and asthmatic lungs. 
Asthmatic ASMCs had increased TET activity and 5hmC content as compared to non-
asthmatic ASMCs. In addition, siTET1 knockdown abrogated TET1 expression and TET 
activity; and attenuated the increased cell proliferation and expression of ASM 
phenotypic genes (PCNA, SMA, CAMK2D, MLCK and TGFβ2) in asthmatic ASMCs. 
Our conclusions our summarized below in Figure 1. These findings support the notion 
that TET1 regulates the asthmatic phenotypes of ASMCs via modulation of the 
expression of ASM phenotypic genes.  In addition to gene expression changes in cell 
contraction genotypes, it would be worthwhile to investigate cell contraction phenotypes 
through optical magnetic twisting cytometry methods which measure ASM cell stiffness 
in response to a bronchiconstrictor and bronchidilator.  
 
We further identified a novel role of oxidative stress in regulating TET activity in 
ASMCs.  We demonstrated that airway oxidative stress levels could alter citrate 
metabolism and the generation of alpha-ketoglutarate (alpha-KG) metabolites, a co-factor 
critical for TET enzymatic activity.  Applying immunomodulator TGFβ1 as a pro-
oxidant, and Sulforaphane (SFN) as an anti-oxidant in both non-asthmatic and asthmatic 
ASMCs we found that TGFβ1 increased citrate metabolism and subsequent TET 
activation while SFN decreased citrate metabolism (IDH1, IDH2, SIRT1 and SIRT3).  
Similarly, these changes in citrate metabolism corresponded to the reduction of alpha-KG 
production and TET activity.  Consequently, TGFβ1 induced more proliferative 
phenotypes in non-asthmatic cells while SFN repressed the increased cell proliferation 
phenotype in asthmatic ASMCs.  Taken together, these findings indicate that oxidative 
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stress levels in ASMCs play a significant role in the generation of alpha-KG metabolites, 
which regulate TET enzymatic activity and are linked to ASMCs phenotypes; 
summarized below in Figure 1.  This mechanism of TET regulation warrants further 
investigation to understand which oxidative stress-related transcription factors and 
signaling pathways are perturbed in asthmatic ASMCs, which may contribute to 
increased level of reactive oxygen species, activity of citrate metabolism IDH enzymes, 
and alpha-KG production.  
 
In conclusion, this thesis demonstrated a new mechanistic pathway of asthma 
pathogenesis in which environmental allergen exposure results in the epigenetic 
regulation of gene expression that modulates ASM function. We identified the role of 
TET1-mediated DNA hydroxymethylation upon AHR through elucidating the epigenetic 
regulation of ASMCs. Also, this work provides new insights into the understanding of 
asthma pathogenesis. Furthermore, we discovered that increased oxidative stress in 
asthmatic ASMCs increased citrate metabolism and the generation of alpha-KG 
metabolites resulting in the up-regulation of TET1 activity.  Dysregulation of TET1 in 
ASMCs leads to persistent changes in the ASM cell phenotype in human asthmatics.  
These results are summarized below in Figure 1. Moreover, we demonstrated that 
antioxidant treatment may be effective in reversing the aberrant ASM cell phenotypes 
seen in asthmatics. We also showed administration to SFN could prevent the epigenetic 
modifications induced by allergen challenge and as such may prevent the long-term 
consequences of allergen sensitization including ASM remodeling and AHR.  These 
results provide unique perspectives on the epigenetic signatures implicated in asthma 
pathogenesis and the possible use of anti-oxidants to modulate TET1-mediated DNA 
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hydroxymethylation to reverse asthmatic ASMC phenotypes. Furthermore, this thesis 
work provides a logical framework to investigate aberrant epigenetic mechanisms, in 
addition to TET1, and how these modifications link to physiopathological changes in the 
lungs. Overall, these results may lead to the development of new therapeutic approaches 
for the treatment of the asthma disease. 
Figure 1. Proposed model of TET1-mediated DNA hydroxymethylation in the 
regulation of asthmatic ASM cells.  Environmental exposures to allergens in the airway 
lumen can induce a pro-allergic Th2 mediated immune response with increased mast cell 
and eosinophils to increase both airway inflammation and oxidative stress. Asthmatic 
airways are characterized by imbalances in oxidative stress homeostasis; with increased 
reactive oxygen species (ROS) produced and decreased anti-oxidant enzymes to mitigate 
the damage.  Increased airway oxidative stress can impact many cell types including the 
airway smooth muscle cells (ASMCs). We demonstrated that increased oxidative stress in 
ASMCs induced citrate metabolism, by increasing IDH1 and IDH2 expression, which 
increased the generation of a-KG, a required co-factor for TET1 enzymatic activity.  
Increased TET1 mediated the increase in 5hmC content. Increased TET1-mediated DNA 
hydroxymethylation in ASMCs corresponded with increased cell proliferation 
phenotypes and the increased gene expression of ASM cell proliferation genes (PCNA, 
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TGFβ2), cell contraction genes (CAMK2D, MLCK) and collagen synthesis genes 
(COL1A, COL3A).  Therefore, our study provides evidence that the up-regulation of 
TET1 alters DNA methylation profiles to increase the gene expression of ASM 
phenotypic genes and alter the phenotypes of ASMCs to be more proliferative and 
contractile, features of asthmatic patients. These changes might persist and ultimately 
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